Research Sample bioBank
Can’t find what you’re looking for? Contact us.
Or, need help ordering? 805.528.4341
Get Weekly Research Sample Updates in your Inbox:
Hepatitis C (HCV) Genotype 1 Clinical Research Samples
Discovery Life Sciences provides the highest quality Hepatitis C (HCV) Genotype 1 Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank.
- All Hepatitis C (HCV) Genotype 1 Sample Orders are Packaged for Delivery within 24 Hours.
- All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
- Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
- Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations.
Advanced Data View:
Showing 262 of 262 total samples
Buy | Product ID | Sample | Matrix | Vial (ml) | Quantity | Price | Age | Gender | Ethnicity | Storage Temp | Sample Date | Test 1 | Test Data 1 | Detail 1 | Test 2 | Test Data 2 | Detail 2 | Test 3 | Test Data 3 | Product Details | Price | Buy | Blood Type | Height | Weight | Symptoms | 3-series HepB Vaccine | Is Subject on Anti-Viral Therapy / Treatment | Acquired Infection Category | Additional Testing | Hepatitis Serology | Co-Infections | HCV Risk Group | Previous HCV Treatment | Genotype |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BBP0000-AA900105561100813DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 6.00 | $200.00 | 37 Y | Female | Non-Hispanic | <-70°C | 08-Oct-13 | Roche cobas | 6,800,000 IU/mL | Genotype | 1b | Per Medical Records | $200.00 | Unknown | Abdominal pain | No | No | Unknown | ALT: 37; AST: 26; ALP: 72; LDH: 168; Bilirubin: 0.4 mg/dL; Serum Creatinine: 0.71 mg/dL; HAI: Staging 0 Grading 3 | |||||||||||||
| BBP0000-CR900105558111114DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 13.00 | $75.00 | 77 Y | Female | Non-Hispanic | < -70C | 11-Nov-14 | Roche cobas | 1,000,000 IU/mL | 11-Sep-14 | Sequencing In-house Assay | 1b | 11-Sep-14 | $75.00 | Unknown | N/A | No | No | Unknown | ALT: 44.8; AST: 40.8; ALP: 55; LDH: 273; Bilirubin: 1.7 mg/dL; Serum Creatinine: 0.69 mg/dL 11-Sep-14 | ||||||||||||
| BBP0000-CR900105559091114DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 2.00 | $75.00 | 64 Y | Male | Non-Hispanic | < -70C | 11-Sep-14 | Roche cobas | 15,000,000 IU/mL | 4-Sep-14 | Genotype | 1a | Test Method Unavailable | $75.00 | Unknown | N/A | No | No | IV Drug Abuse | ALT: 138; AST: 82; ALP: 74; LDH: 207; Bilirubin: 0.5 mg/dL; Serum Creatinine: 1.08 mg/dL; Fibroscan 14.1 kPa; (Biopsy F2 Mar-2006) 3-Sep-14 | ||||||||||||
| BBP0000-CR900105562101113DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.25 | 1.00 | $200.00 | 51 Y | Male | Non-Hispanic | <-70°C | 11-Oct-13 | Roche cobas | 5,500,000 IU/mL | Genotype | 1a | Per Medical Records | $200.00 | Unknown | No symptoms | No | No | Surgery | ALT: 12; AST: 27; ALP: 39; LDH: 186; Bilirubin: 0.3 mg/dL; Serum Creatinine: 0.79 mg/dL; HAI: Staging 1 Grading 0 | |||||||||||||
| BBP0000-FI900105563022613DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.25 | 1.00 | $200.00 | 54 Y | Male | Non-Hispanic | <-70°C | 26-Feb-13 | Roche cobas | 1,717,375 IU/mL | Genotype | 1a | Per Medical Records | $200.00 | Unknown | Fatigue; Depression | Yes | No | Occupational Working Firefighter | ALT: 42; AST: 35; ALP: 81; Biopsy: G1 S1 | |||||||||||||
| BBS0000-CV900104758110716DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 57 Y | Male | Non-Hispanic | <-70C | 07-Nov-16 | Roche cobas | 7,230,000 IU/mL | 4-Nov-16 | Lightpower HCV Genotype Rt-PCR | 1 | 9-Nov-16 | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain | No | No | Unknown | ALT: 309 U/L; AST: 931 U/L; Bilirubin: 15.5 umol/L; Serum Creatinine: 95 umol/L 2-Nov-16 | HCV Ab + (Architect plus cobas) 28-Oct-16 | N/A | ||||||||||
| BBS0000-CV900106429071014DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 56 Y | Female | Non-Hispanic | < -70C | 10-Jul-14 | Roche HCV Monitor | 1,150,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 199; AST: 241; Bilirubin: 11.3 umol/L; Serum Creatinine: 0.8 mg/dL | ||||||||||||||
| BBS0000-CV900106430061314DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 43 Y | Male | Non-Hispanic | < -70C | 13-Jun-14 | Roche HCV Monitor | 2,600,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Abdominal pain; Sleep disturbances | No | No | Unknown | ALT: 114; AST: 132; Bilirubin: 65 umol/L; Serum Creatinine: 1.12 mg/dL | Anti HCV+ (Elisa) | None | ||||||||||||
| BBS0000-CV900106677072914DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 58 Y | Female | Non-Hispanic | < -70C | 29-Jul-14 | Roche cobas | 4,200,000 copies/mL | 18-Jul-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Oct-14 | $200.00 | Unknown | Fatigue | No | No | Unknown | ALT: 54; AST: 60; ALP: 61; Bilirubin: 10 umol/L; Serum Creatinine: 67 umol/L 12-Jul-14 | ||||||||||||
| BBS0000-CV900106678051314DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 4.00 | $200.00 | 56 Y | Female | Non-Hispanic | < -70C | 13-May-14 | Roche cobas | 77,200,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Itching; Sleep disturbances | No | No | Sexual Transmission; IV Drug Abuse | ALT: 127; AST: 261; ALP: 88; Bilirubin: 14.3 umol/L; Serum Creatinine: 0.8 mg/dL | ||||||||||||||
| BBS0000-CV900106679052214DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 39 Y | Male | Non-Hispanic | < -70C | 22-May-14 | Roche cobas | 452,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Sexual Transmission | ALT: 156; AST: 20; Bilirubin: 8.3 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2011 | ||||||||||||
| BBS0000-CV900106680071514DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 27 Y | Male | Non-Hispanic | < -70C | 15-Jul-14 | Roche cobas | 1,700 IU/mL | 13-Jun-14 | Lightpower HCV Genotype Rt-PCR | 1 | 18-Jul-14 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | IV Drug Abuse | ALT: 143; AST: 37; Serum Creatinine: 96 umol/L 9-Jul-14 | HBsAg - (Elisa) 15-Jun-14 | |||||||||||
| BBS0000-CV900106681082014DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 40 Y | Male | Non-Hispanic | < -70C | 20-Aug-14 | Roche cobas | 27,400 IU/mL | 15-Aug-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Oct-14 | $200.00 | Unknown | Fatigue; Nausea | No | No | Unknown | ALT: 47; AST: 37 6-Aug-14 | ||||||||||||
| BBS0000-CV900111495121114DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 5.00 | $200.00 | 44 Y | Male | Non-Hispanic | < -70C | 11-Dec-14 | Roche cobas | 1,000,000 copies/mL | 27-Nov-14 | Lightpower HCV Genotype Rt-PCR | 1 | 16-Dec-14 | $200.00 | Unknown | Fatigue; Itching | no | Yes Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | IV Drug Abuse | ALT: 37 U/L; AST: 124 U/L; Serum Creatinine: 62 umol/dL 27-Nov-14 | HBsAg -; Anti HCV + (Elisa) 14-May-08 | HIV Positive 1-Jul-08 | ||||||||||
| BBS0000-EN900097411071213DD | Hepatitis C (HCV) Genotype 1 | Serum | 0.75 | 10.00 | $200.00 | 39 Y | Male | Hispanic | <-70C | 12-Jul-13 | Abbott | <12 IU/mL | 12-Jul-13 | HCV Genotype | 1 | HCV Date of Diagnosis | 2002 | $200.00 | Unknown | 66.93 | 154 | None | Body piercing Tattooing | Yes | 2010 IFN & Ribavirin ended 2011 | |||||||||||
| BBS0000-EN900098443070513DD | Hepatitis C (HCV) Genotype 1 | Serum | 0.75 | 6.00 | $200.00 | 57 Y | Male | Hispanic | <-70C | 05-Jul-13 | Abbott | <12 IU/mL | 5-Jul-13 | HCV Genotype | 1 | HCV Date of Diagnosis | 1999 | $200.00 | Unknown | 66.14 | 169 | None | U/A | Yes | Oct-2006 IFN & Ribavirin ended Apr-2007 | |||||||||||
| BBS0000-EN900098443081213DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 58 Y | Male | Hispanic | <-70C | 12-Aug-13 | Abbott | <12 IU/mL | 12-Aug-13 | HCV Genotype | 1 | HCV Date of Diagnosis | 1999 | $200.00 | Unknown | 66.14 | 169 | None | U/A | Yes | Oct-2006 IFN & Ribavirin ended Apr-2007 | |||||||||||
| BBS0000-EN900105396090617DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 73 Y | Female | Non-Hispanic | <-70C | 06-Sep-17 | Roche cobas | 2,080,000 IU/mL | 7-Jul-17 | Siemens TruGene HCV 5NC | 1b | 7-Jul-17 | HCV Date of Diagnosis | 27-Jun-17 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 140 U/L | AST: 96 U/L | Bilirubin: 1.2 mg/dL | Serum Creatinine: 0.69 mg/dL | | 4-Mar-2017 | ALP: 171 U/L | Liver Cirrhosis from Chronic HCV 2-Sep-17 | HBsAg-, HBsAb+, HBcAb+, 6-Apr-17 | None | ||||||||
| BBS0000-EN900105397092717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 69 Y | Male | Non-Hispanic | <-70C | 27-Sep-17 | Roche cobas | 284,000 IU/mL | 3-May-17 | Siemens TruGene HCV 5NC | 1b | 3-May-17 | HCV Date of Diagnosis | 8-May-15 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 40 U/L | AST: 88 U/L | Bilirubin: 0.51 mg/dL | Serum Creatinine: 1.0 mg/dL | | 3-May-2017 | ALP: 111 U/L | Chronic Hepatitis C 27-Sep-17 | HBsAg-, HBsAb+, HBcAb+, 3-May-17 | None | ||||||||
| BBS0000-EN900105399091317DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 55 Y | Female | Non-Hispanic | <-70C | 13-Sep-17 | Roche cobas | 337,000 IU/mL | 24-Apr-17 | Siemens TruGene HCV 5NC | 1b | 24-Apr-17 | HCV Date of Diagnosis | 24-Apr-17 | $200.00 | Unknown | Fatigue | No | No | U/A | ALT: 20 U/L | AST: 24 U/L | | Bilirubin: 1.5 mg/dL | Serum Creatinine: 0.82 mg/dL | Chronic Hepatitis C 11-Sep-17 | HBsAg-, HBsAb-, HBcAb-, 24-Apr-17 | None | ||||||||
| BBS0000-EN900105400102517DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 76 Y | Female | Non-Hispanic | <-70C | 25-Oct-17 | Roche cobas | 4,060,000 IU/mL | 1-Sep-17 | Siemens TruGene HCV 5NC | 1b | 1-Oct-17 | HCV Date of Diagnosis | 10-Aug-15 | $200.00 | Unknown | Fatigue | No | No | U/A | ALT: 42 U/L | AST: 42 U/L | Serum Creatinine: 0.7 mg/dL | 31-Aug-2017 | Bilirubin: 0.5 mg/dL | Chronic Hepatitis C 19-Oct-17 | HBsAg-, HBsAb-, HBcAb+, 31-Aug-17 | None | ||||||||
| BBS0000-EN900107445122017DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 73 Y | Male | Non-Hispanic | <-70C | 20-Dec-17 | Roche cobas | 8,970,000 IU/mL | HCV Viral Load | Genotype | 1b | 7-Jul-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | Fatigue | No | U/A | ALT: 91 U/L | AST: 55 U/L | Creatinine: 1.04 mg/dL | Chronic Hepatitis C 11-Dec-17 | HBsAg- | HBsAb+ | HBcAb+ | (CMIA) 11-Aug-17 | None | |||||||||
| BBS0000-EN900109384073013DD | Hepatitis C (HCV) Genotype 1 | Serum | 0.75 | 10.00 | $200.00 | 53 Y | Male | Non-Hispanic | <-70C | 30-Jul-13 | Abbott | <12 IU/mL | 30-Jul-13 | HCV Genotype | 1 | HCV Date of Diagnosis | 2008 | $200.00 | Unknown | 62.99 | 176 | None | Sexual transmission | Yes | 2010 IFN & Ribavirin ended 2011 | |||||||||||
| BBS0000-FI900105557020413DD | Hepatitis C (HCV) Genotype 1 | Serum | 0.25 | 1.00 | $200.00 | 38 Y | Male | Hispanic | <-70°C | 04-Feb-13 | Roche cobas | 1,009,903 IU/mL | Innogenetics Versant HCV | 1b | $200.00 | Unknown | Fatigue | No | No | Sexual Transmission | ALT: 43; AST: 34; ALP: 76; Bilirubin: 0.5 | Hep C Antibody+; HBsAg- | |||||||||||||
| BBS0005-AM900050646042417DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.50 | 1.00 | $75.00 | Female | Unknown | <-70C | 24-Apr-17 | RT-PCR | Positive | HCV | $75.00 | Unknown | 1b | ||||||||||||||||||||
| BBS0005-AM900050648092717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 1.00 | $75.00 | Male | Unknown | <-70C | 27-Sep-17 | RT-PCR | 5090000 IU/mL | HCV | HCV Log: 6.7 | $75.00 | Unknown | 1a | |||||||||||||||||||
| BBS0005-AM900087119110119DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.75 | 1.00 | $75.00 | 25 Y | Male | Unknown | <-70C | 01-Nov-19 | RT-PCR | Positive | HCV | $75.00 | Unknown | 1a | |||||||||||||||||||
| BBS0005-AM900087120110119DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.50 | 1.00 | $75.00 | 30 Y | Female | Unknown | <-70C | 01-Nov-19 | RT-PCR | Positive | HCV | $75.00 | Unknown | 1a | |||||||||||||||||||
| BBS0005-AM900087125110119DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.50 | 1.00 | $75.00 | 32 Y | Male | Unknown | <-70C | 01-Nov-19 | RT-PCR | Positive | HCV | $75.00 | Unknown | 1a | |||||||||||||||||||
| BBS0005-AM900087126110119DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.25 | 1.00 | $75.00 | 25 Y | Female | Unknown | <-70C | 01-Nov-19 | RT-PCR | Positive | HCV | $75.00 | Unknown | 1a | |||||||||||||||||||
| BBS0005-AM900087127110119DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.25 | 1.00 | $75.00 | 19 Y | Female | Unknown | <-70C | 01-Nov-19 | RT-PCR | Positive | HCV | $75.00 | Unknown | 1a | |||||||||||||||||||
| BBS0005-CJ900023220112112DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 5.00 | $200.00 | 32 Y | Male | Non-Hispanic | < -70C | 21-Nov-12 | Roche cobas | 3,280,000 IU/mL | 23-Aug-12 | Siemens TreGene HCV | 1a | 2006 | $200.00 | Unknown | Abdominal Pain, Nausea | Yes | No | IV Drug Abuse | ALT: 90; AST: 43; ALP: 172; Bilirubin: 0.44; Liver Disease Diagnosis: Chronic Hepatitis 23-Aug-12 | anti HCV+ (Abbott) 2006 | |||||||||||
| BBS0005-CJ900061189051012DD | Hepatitis C (HCV) Genotype 1 | Serum | 0.50 | 1.00 | $75.00 | 63 Y | Female | Unknown | <-70°C | 10-May-12 | Real-Time PCR | 18,757,920 IU/mL | Siemens TruGene HCV | 1b | $75.00 | Unknown | Sleep disturbances | No | No | Transfusion | ALT: 32; AST: 47; Serum Creatinine: 1.1 mg/dL; Liver Disease Diagnosis: 2008; Chronic Hepatitis 2012 | anti HCV+ (Abbott) | |||||||||||||
| BBS0005-CJ900061193061912DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 1.00 | $200.00 | 55 Y | Female | Unknown | <-70°C | 19-Jun-12 | Real-Time PCR | 183,437 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Depression | No | No | Surgery | ALT: 33 AST: 57 ALP: 122 LDH: 480 Bilirubin: 3.95 Serum Creatinine: 0.62 mg/dL Liver Disease Diagnosis: 2009 Hepatocellular Carcinoma 2012 | anti HCV+ (Abbott) | |||||||||||||
| BBS0005-CL900041690021413DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 1.00 | $200.00 | 49 Y | Female | Non-Hispanic | <-70°C | 14-Feb-13 | Quantitative HCV RNA Assay | 180,965 IU/mL | Siemens Trugene HCV | 1b | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain; Flu-like symptoms; Joint pain; Nausea; Depression | Yes | No | Sexual transmission; Rape, Sodomized | ALT: 65; AST: 82 ALP: 148; Bilirubin: 0.61; Serum Creatinine: 0.8 mg/dL | ||||||||||||||
| BBS0005-CV900023306052715DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 4.00 | $200.00 | 35 Y | Male | Non-Hispanic | <-70C | 27-May-15 | Roche cobas | 1,940,000 copies/mL | 23-Apr-15 | Lightpower HCV Genotype Rt-PCR | 1 | 9-Jul-15 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir 300 mg, Lamivudine 150 mg, Efavirenz 600 mg | Sexual transmission , IV Drug Abuse | |||||||||||||
| BBS0005-CV900023318051315DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 37 Y | Male | Non-Hispanic | <-70C | 13-May-15 | Roche cobas | 4,900 copies/mL | 28-Jan-15 | Lightpower HCV Genotype Rt-PCR | 1 | 13-Mar-15 | $200.00 | Unknown | No symptoms | No | Yes | IV Drug Abuse | ALT: 25 U/L; AST: 90 U/L; Serum Creatinine: 99 umol/L 14-Aug-14 | HBsAg -; Anti HCV + (Elisa) 20-Jan-14 | |||||||||||
| BBS0005-CV900023320081215DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 5.00 | $200.00 | 40 Y | Male | Non-Hispanic | <-70C | 12-Aug-15 | Roche cobas | 52,000,000 copies/mL | 5-May-15 | Lightpower HCV Genotype Rt-PCR | 1 | 20-Aug-15 | $200.00 | Unknown | No symptoms | No | No | Unknown | |||||||||||||
| BBS0005-CV900027300112916DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 41 Y | Female | Non-Hispanic | <-70C | 29-Nov-16 | Roche cobas | 2,160,000 IU/mL | 24-Nov-16 | Lightpower HCV Genotype Rt-PCR | 1 | 1-Dec-16 | $200.00 | Unknown | Decreased appetite; Fatigue; Sleep disturbances | No | No | Unknown | ALT: 117 U/L; AST: 251 U/L; Bilirubin: 15.4 umol/L; Serum Creatinine: 61 umol/L 25-Nov-16 | HCV Ab + (cobas 6000E) 21-Nov-16 | N/A | ||||||||||
| BBS0005-CV900027314120116DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 39 Y | Female | Non-Hispanic | <-70C | 01-Dec-16 | Roche Cobas | 4,450,000 IU/mL | 29-Nov-16 | $200.00 | Unknown | Fatigue | No | Yes Tenofovir; Lamivudine; Efavirenz | Sexual Transmission | ALT: 37 U/L, AST: 29 U/L, Serum Creatinine: 62 umol/L 24-Nov-16 | None | HIV+ 19-Mar-14 | |||||||||||||
| BBS0005-CV900027315011117DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 75 Y | Male | Non-Hispanic | <-70C | 11-Jan-17 | Roche Cobas | 13,800 copies/mL | 9-Jan-17 | $200.00 | Unknown | Fatigue | Partial | No None | Unknown | ALT: 110 U/L, AST: 90 U/L 4-Jan-17 | None | None | |||||||||||||
| BBS0005-CV900027317030217DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 49 Y | Female | Non-Hispanic | <-70C | 02-Mar-17 | Roche Cobas | 2,100,000 IU/mL | 1-Mar-17 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No None | Unknown | ALT: 206 U/L, AST: 260 U/L, Serum Creatinine: 97 umol/LHCV, 2017 27-Feb-17 | None | None | |||||||||||||
| BBS0005-CV900028244051314DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 19.00 | $200.00 | 54 Y | Male | Non-Hispanic | < -70C | 13-May-14 | Roche cobas | 9,320 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Depression | No | No | Unknown | ALT: 172; AST: 149; Bilirubin: 18.1 umol/L; Serum Creatinine: 0.77 mg/dL; ALP: 105 | ||||||||||||||
| BBS0005-CV900028245051214DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 7.00 | $200.00 | 57 Y | Female | Non-Hispanic | < -70C | 12-May-14 | Roche cobas | 1,160 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain; Jaundice; Sleep disturbances | No | No | Unknown | ALT: 597; AST: 444; LDH: 294; Bilirubin: 199.6 umol/L; Serum Creatinine: 0.68 mg/dL | ||||||||||||||
| BBS0005-CV900028247032514DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 63 Y | Male | Non-Hispanic | < -70C | 25-Mar-14 | Roche cobas | 705,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Depression | No | No | Unknown | ALT: 122 U/L; AST: 191 U/L | ||||||||||||||
| BBS0005-CV900028249091014DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 36 Y | Male | Non-Hispanic | < -70C | 10-Sep-14 | Roche cobas | 67,900 IU/mL | 5-Sep-14 | Lightpower HCV Genotype Rt-PCR | 1 | 13-Oct-14 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 44; AST: 116; Bilirubin: 7.2 umol/L; Serum Creatinine: 1.1 mg/dL 28-Aug-14 | ||||||||||||
| BBS0005-CV900032013042717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 8.00 | $200.00 | 42 Y | Male | Non-Hispanic | <-70C | 27-Apr-17 | Roche Cobas | 12,100,000 IU/mL | 27-Apr-17 | Lightpower HCV Genotype Rt-PCR | 1 | 5-May-17 | 3-series HepB Vaccine | Yes | $200.00 | Unknown | Itching; Depression | None | IV Drug Abuse | ALT: 68 U/L | AST: 42 U/L | Bilirubin: 14.2 umol/L | Serum Creatinine: 62 umol/L 26-Mar-17 | None | HIV+ | 1-Jul-2005 | CD4 - 190 15-Sep-2016 | |||||||||
| BBS0005-CV900032015120516DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 58 Y | Male | Non-Hispanic | <-70C | 05-Dec-16 | Roche Cobas | 95,000 IU/mL | 4-Dec-16 | $200.00 | Unknown | Fatigue | No | No None | Sexual Transmission | ALT: 120 U/L, AST: 81 U/L 23-Nov-16 | None | None | |||||||||||||
| BBS0005-CV900032016122716DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 33 Y | Female | Non-Hispanic | <-70C | 27-Dec-16 | Roche Cobas | 436,000 copies/mL | 26-Dec-16 | $200.00 | Unknown | Fatigue | Partial | Yes Tenofovir; Lamivudine; Efavirenz | Sexual Transmission | ALT: 102 U/L, AST: 61 U/L, Serum Creatinine: 62 umol/L 15-Dec-16 | None | HIV+ 4-Dec-13 | |||||||||||||
| BBS0005-CV900032017032917DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 34 Y | Female | Non-Hispanic | <-70C | 29-Mar-17 | Roche Cobas | 8,260,000 IU/mL | 27-Mar-17 | $200.00 | Unknown | Fatigue; Abdominal pain | No | No None | Unknown | ALT: 46 U/L, AST: 51 U/L, Bilirubin: 17.6 umol/L, Serum Creatinine: 63 umol/L, Chronic HCV 2010 20-Mar-17 | HCV Ab + | AIDS+ 2010 | |||||||||||||
| BBS0005-CV900033408072115DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 56 Y | Male | Non-Hispanic | <-70C | 21-Jul-15 | Roche cobas | 3,900,000 IU/mL | 16-Jul-15 | Lightpower HCV Genotype Rt-PCR | 1 | 7-Aug-15 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | |||||||||||||
| BBS0005-CV900033411110514DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 41 Y | Male | Non-Hispanic | < -70C | 05-Nov-14 | Roche cobas | 187,000 copies/mL | 10-Jul-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Nov-14 | $200.00 | Unknown | Fatigue | No | No | Unknown | ALT: 97 U/L; AST: 122 U/L; Serum Creatinine: 66 umol/L 7-Jun-14 | HBsAg -; Anti HCV + (Elisa) 20-Jun-10 | |||||||||||
| BBS0005-CV900033419102814DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 4.00 | $200.00 | 53 Y | Female | Non-Hispanic | < -70C | 28-Oct-14 | Roche cobas | 131,000 IU/mL | 14-Oct-14 | Lightpower HCV Genotype Rt-PCR | 1 | 29-Oct-14 | $200.00 | Unknown | Fatigue; Itching | No | No | Sexual Transmission | ALT: 274 U/L; AST: 223 U/L 14-Oct-14 | Anti HCV + (Elisa) 14-Oct-14 | |||||||||||
| BBS0005-CV900033422110714DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 35 Y | Male | Non-Hispanic | < -70C | 07-Nov-14 | Roche cobas | 51,200,000 copies/mL | 26-Aug-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Nov-14 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Aluvia 200/50 mg | IV Drug Abuse | ALT: 69 U/L; AST: 47 U/L 21-Aug-14 | HBsAg -; Anti HCV + (Elisa) 21-Aug-14 | HIV + 1-Jul-03 | ||||||||||
| BBS0005-CV900035995042313DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 1.00 | $200.00 | 41 Y | Male | Non-Hispanic | <-70°C | 23-Apr-13 | Roche cobas | 1,590,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Jaundice; Flu-like symptoms | No | No | Unknown | ALT: 135; AST: 125; ALP: 107; Bilirubin: 30 umol/L; Serum Creatinine: 66 umol/L | HBsAg- (ECLIA Cobas 6000) | |||||||||||||
| BBS0005-CV900035996073013DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 40 Y | Male | Non-Hispanic | <-70°C | 30-Jul-13 | Roche cobas | 460,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Sexual Transmission | ALT: 114 U/L; AST: 73 U/L; Serum Creatinine: 7.3 umol/L | HBsAg+; Anti HCV+ (Elisa) | HIV+ 2008 | ||||||||||||
| BBS0005-CV900035997070513DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 3.00 | $200.00 | 58 Y | Male | Non-Hispanic | <-70°C | 05-Jul-13 | Roche cobas | 1,160,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 24; AST: 95; Bilirubin: 16.1 umol/L | Anti HCV+ (ECLIA Cobas 6000) | |||||||||||||
| BBS0005-CV900035998071813DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 1.00 | $200.00 | 41 Y | Male | Non-Hispanic | <-70°C | 18-Jul-13 | Roche cobas | 22,600,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Fatigue; Joint pain; Sleep disturbances | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | IV Drug Abuse | ALT: 42; AST: 39; Serum Creatinine: 88 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2012 | ||||||||||||
| BBS0005-CV900036016100615DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 51 Y | Male | Non-Hispanic | <-70C | 06-Oct-15 | Roche cobas | 5,890,000 IU/mL | 24-Sep-15 | Lightpower HCV Genotype Rt-PCR | 1 | 8-Oct-15 | $200.00 | Unknown | Fatigue | ||||||||||||||||
| BBS0005-CV900036017090815DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 31 Y | Male | Non-Hispanic | <-70C | 08-Sep-15 | Roche cobas | 695,000 IU/mL | 4-Sep-15 | Lightpower HCV Genotype Rt-PCR | 1 | 10-Sep-15 | $200.00 | Unknown | Decreased appetite; Fatigue; Jaundice | No | No | Unknown | |||||||||||||
| BBS0005-CV900036020100215DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 57 Y | Female | Non-Hispanic | <-70C | 02-Oct-15 | Lightpower HCV Genotype Rt-PCR | 1 | 8-Oct-15 | $200.00 | Unknown | Fatigue; Fever; Cough | |||||||||||||||||||
| BBS0005-CV900036021091015DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 70 Y | Female | Non-Hispanic | <-70C | 10-Sep-15 | Roche cobas | 11,720,000 IU/mL | 8-Sep-15 | Lightpower HCV Genotype Rt-PCR | 1 | 17-Sep-15 | $200.00 | Unknown | Fatigue; Nausea | ||||||||||||||||
| BBS0005-CV900037449111014DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 35 Y | Male | Non-Hispanic | < -70C | 10-Nov-14 | Roche cobas | 3,550,000 copies/mL | 10-Sep-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Nov-14 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | IV Drug Abuse | ALT: 48 U/L; AST: 69 U/L 20-Aug-14 | HBsAg -; Anti HCV + (Elisa) 17-Jul-2013; 30-Jul-2013 | HIV + 17-Jul-13 | ||||||||||
| BBS0005-CV900037450012915DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 65 Y | Male | Non-Hispanic | < -70C | 29-Jan-15 | Roche cobas | 75,600 IU/mL | 23-Jan-15 | Lightpower HCV Genotype Rt-PCR | 1 | 4-Feb-15 | $200.00 | Unknown | Fatigue; Jaundice | Partial | No None | Unknown | ALT: 150 U/L; AST: 120 U/L; Bilirubin: 20.5 umol/L; Serum Creatinine: 85 umol/dL 20-Jan-15 | None | |||||||||||
| BBS0005-CV900037453092414DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 16.00 | $200.00 | 38 Y | Male | Non-Hispanic | < -70C | 24-Sep-14 | Roche cobas | 6,220,000 IU/mL | 16-Sep-14 | Lightpower HCV Genotype Rt-PCR | 1 | 13-Oct-14 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 49 U/L; AST: 85 U/L; Bilirubin: 8.0 umol/L; Serum Creatinine: 1.0 mg/dL 11-Sep-14 | ||||||||||||
| BBS0005-CV900037455011515DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 8.00 | $200.00 | 39 Y | Male | Non-Hispanic | < -70C | 15-Jan-15 | Roche cobas | 5,050,000 copies/mL | 3-Dec-14 | Lightpower HCV Genotype Rt-PCR | 1 | 22-Jan-15 | $200.00 | Unknown | Joint pain; Sleep Disturbances | Yes | Yes Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | IV Drug Abuse | ALT: 101 U/L; AST: 110 U/L; Serum Creatinine: 74 umol/L 17-Nov-14 | HBsAg -; Anti HCV + (Elisa) 4-Aug-11 | HIV Positive 1-Jul-01 | ||||||||||
| BBS0005-CV900039259062813DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 7.00 | $200.00 | 37 Y | Male | Non-Hispanic | < -70C | 28-Jun-13 | Roche cobas | 32,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | No symptoms | No | Yes Zidovudine 300 mg; Lamivudine 150 mg; Tenofovir 300 mg; Lopinavir / Ritonavir 200 mg / 50 mg | Sexual Transmission; IV Drug Abuse | ALT: 25 U/L; AST: 25 U/L; Serum Creatinine: 103 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2006 | ||||||||||||
| BBS0005-CV900041863051314DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 62 Y | Female | Non-Hispanic | < -70C | 13-May-14 | Roche cobas | 1,300,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Sleep disturbances | No | No | Unknown | ALT: 113; AST: 119; ALP: 61; Bilirubin: 15.7 umol/L; Serum Creatinine: 0.8 mg/dL | ||||||||||||||
| BBS0005-CV900041864041614DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 40 Y | Male | Non-Hispanic | < -70C | 16-Apr-14 | Roche cobas | 55,200,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain; Jaundice | No | No | Unknown | ALT: 1435; AST: 2679; Bilirubin: 185.7 umol/L; Serum Creatinine: 1.0 mg/dL; Hepatitis C | ||||||||||||||
| BBS0005-CV900041865081514DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 7.00 | $200.00 | 26 Y | Male | Non-Hispanic | < -70C | 15-Aug-14 | Roche cobas | 1,170,000 IU/mL | 15-Aug-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Oct-14 | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain | No | No | IV Drug Abuse | |||||||||||||
| BBS0005-CV900041869031914DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 58 Y | Male | Non-Hispanic | < -70C | 19-Mar-14 | Roche cobas | 225,000 copies/mL | HCV | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain; Jaundice; Sleep disturbances | No | No | Unknown | ALT: 46; AST: 15; Bilirubin: 38.1 umol/L; Serum Creatinine: 1.0 mg/dL | HBV+ 2010 | ||||||||||||
| BBS0005-CV900046718111313DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 37 Y | Male | Non-Hispanic | < -70C | 13-Nov-13 | Roche cobas | 11,700,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Jaundice; Flu-like symptoms; Nausea | No | No | Unknown | ALT: 521 U/L; AST: 480 U/L; Bilirubin: 97.7 umol/L; Serum Creatinine: 93 umol/L | HBsAg-; Anti HCV+ (Elisa) | |||||||||||||
| BBS0005-CV900046721120613DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 8.00 | $200.00 | 50 Y | Male | Non-Hispanic | < -70C | 06-Dec-13 | Roche cobas | 9,870 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 220 U/L; AST: 82 U/L; ALP: 96 U/L; Bilirubin: 55 umol/L; Serum Creatinine: 89 umol/L | HBsAg-; Anti HCV+ (ECLIA Cobas 6000) | |||||||||||||
| BBS0005-CV900047641080114DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 54 Y | Female | Non-Hispanic | < -70C | 01-Aug-14 | Roche cobas | 96,000 copies/mL | 16-Jul-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Oct-14 | $200.00 | Unknown | Decreased appetite; Abdominal pain | No | No | Unknown | ALT: 254; AST: 583 16-Jul-14 | ||||||||||||
| BBS0005-CV900047646090814DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 44 Y | Male | Non-Hispanic | < -70C | 08-Sep-14 | Roche cobas | 900,000 IU/mL | 5-Sep-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Oct-14 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 53; AST: 18; Bilirubin: 5.6 umol/L; Serum Creatinine: 1.08 mg/dL 28-Aug-14 | ||||||||||||
| BBS0005-CV900047648100314DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 5.00 | $200.00 | 45 Y | Male | Non-Hispanic | < -70C | 03-Oct-14 | Roche cobas | 4,020,000 copies/mL | 17-Sep-14 | Lightpower HCV Genotype Rt-PCR | 1 | 13-Oct-14 | $200.00 | Unknown | Decreased appetite; Fatigue | No | Yes Zidovudine 300 mg; Lamivudine 150 mg; Nevirapine 200 mg | Sexual Transmission; IV Drug Abuse | ALT: 1046; AST: 647; 11-Sep-14 | HBsAg -; Anti HCV + (Elisa) 27-Sep-10; 5-Oct-2010 | HIV+ 27-Sep-10 | ||||||||||
| BBS0005-CV900048755082815DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 38 Y | Male | Non-Hispanic | <-70C | 28-Aug-15 | Roche cobas | 15,200,000 IU/mL | 13-Aug-15 | Lightpower HCV Genotype Rt-PCR | 1 | 3-Sep-15 | $200.00 | Unknown | Decreased appetite | No | No | Unknown | |||||||||||||
| BBS0005-CV900048757091715DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 20 Y | Male | Non-Hispanic | <-70C | 17-Sep-15 | Lightpower HCV Genotype Rt-PCR | 1 | 18-Sep-15 | $200.00 | Unknown | Decreased appetite | |||||||||||||||||||
| BBS0005-CV900048763093015DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 38 Y | Male | Non-Hispanic | <-70C | 30-Sep-15 | Lightpower HCV Genotype Rt-PCR | 1 | 1-Oct-15 | $200.00 | Unknown | No symptoms | |||||||||||||||||||
| BBS0005-CV900052422100614DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 4.00 | $200.00 | 35 Y | Male | Non-Hispanic | < -70C | 06-Oct-14 | Roche cobas | 11,500 copies/mL | 4-Sep-14 | Lightpower HCV Genotype Rt-PCR | 1 | 13-Oct-14 | $200.00 | Unknown | Decreased appetite; Fatigue | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Sexual Transmission; IV Drug Abuse | ALT: 181; AST: 129; Serum Creatinine: 92 umol/L 4-Jun-14 | HIV+ 18-Apr-14 | |||||||||||
| BBS0005-CV900052425041014DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 52 Y | Female | Non-Hispanic | < -70C | 10-Apr-14 | Roche cobas | 52,200,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Sleep disturbances | No | No | Transfusion | ALT: 1102 U/L; AST: 1037 U/L; Bilirubin: 18 umol/L | ||||||||||||||
| BBS0005-CV900052426063014DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 8.00 | $200.00 | 41 Y | Male | Non-Hispanic | < -70C | 30-Jun-14 | Roche cobas | 1,750,000 copies/mL | 26-Jun-14 | Lightpower HCV Genotype Rt-PCR | 1 | 7-Jul-14 | $200.00 | Unknown | No symptoms | Partial | Yes Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Sexual Transmission | ALT: 77; AST: 74; Serum Creatinine: 105 umol/L 27-May-14 | HBsAg -; Anti HCV + (Elisa) 27-May-14 | HIV+ 16-May-14 | ||||||||||
| BBS0005-CV900052428061314DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 58 Y | Female | Non-Hispanic | < -70C | 13-Jun-14 | Eppendorf Real Time PCR | 6,250,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Fatigue; Jaundice | No | No | Unknown | ALT: 282; AST: 478; Bilirubin: 43.3 umol/L; Serum Creatinine: 0.97 mg/dL | ||||||||||||||
| BBS0005-CV900052429042914DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 64 Y | Female | Non-Hispanic | < -70C | 29-Apr-14 | Roche cobas | 1,920,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Abdominal pain; Jaundice | No | No | Unknown | ALT: 149; AST: 437; Bilirubin: 74.2 umol/L; Serum Creatinine: 58 umol/L | Anti HCV+ | None | ||||||||||||
| BBS0005-CV900052430081814DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 5.00 | $200.00 | 31 Y | Male | Non-Hispanic | < -70C | 18-Aug-14 | Roche cobas | 7,070 IU/mL | 21-May-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Oct-14 | $200.00 | Unknown | Decreased appetite; Fatigue; Jaundice | No | No | Transfusion | ALT: 20; AST: 30; Serum Creatinine: 1.08 mg/dL 13-May-14 | Anti HCV + 13-May-14 | |||||||||||
| BBS0005-CV900053312091013DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 2.00 | $200.00 | 37 Y | Male | Non-Hispanic | < -70C | 10-Sep-13 | Roche cobas | 11,700,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Aluvia 200/50 mg | IV Drug Abuse | ALT: 118 U/L; AST: 64 U/L; Serum Creatinine: 88 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 1998 | ||||||||||||
| BBS0005-CV900053313062713DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 5.00 | $200.00 | 39 Y | Male | Non-Hispanic | < -70C | 27-Jun-13 | Roche cobas | 7,170,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Sleep disturbances | No | No | Sexual Transmission; IV Drug Abuse | ALT: 106 U/L; AST: 61 U/L; Serum Creatinine: 83 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2006 | ||||||||||||
| BBS0005-CV900053314072613DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 2.00 | $200.00 | 37 Y | Male | Non-Hispanic | < -70C | 26-Jul-13 | Roche cobas | 10,800,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue | Yes | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Sexual Transmission; IV Drug Abuse | ALT: 72 U/L; AST: 48 U/L; Serum Creatinine: 91 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2011 | ||||||||||||
| BBS0005-CV900053316072413DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 1.00 | $200.00 | 34 Y | Male | Non-Hispanic | < -70C | 24-Jul-13 | Roche cobas | 21,800,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Jaundice; Weight loss | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | IV Drug Abuse | ALT: 20; AST: 11; Bilirubin: 5.7 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2013 | ||||||||||||
| BBS0005-CV900053317061913DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 2.00 | $200.00 | 42 Y | Male | Non-Hispanic | < -70C | 19-Jun-13 | Roche cobas | 31,500,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Fatigue | No | No | Sexual Transmission; IV Drug Abuse | ALT: 67; AST: 97 | HBsAg-; Anti HCV+ | HIV+ 2012 | ||||||||||||
| BBS0005-CV900056100122313DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 5.00 | $200.00 | 47 Y | Male | Non-Hispanic | < -70C | 23-Dec-13 | Roche cobas | 50,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Diabetes | No | No | Transfusion | ALT: 592 U/L; AST: 209 U/L; Bilirubin: 15 umol/L; Serum Creatinine: 71 umol/L | ||||||||||||||
| BBS0005-CV900056102111313DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 18.00 | $200.00 | 37 Y | Male | Non-Hispanic | < -70C | 13-Nov-13 | Roche cobas | 1,570,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Jaundice | No | No | Unknown | ALT: 213 U/L; AST: 84 U/L; Bilirubin: 78 umol/L; Serum Creatinine: 93 umol/L | HBsAg- (ECLIA Cobas 6000) | |||||||||||||
| BBS0005-CV900056185092916DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 40 Y | Female | Non-Hispanic | <-70C | 29-Sep-16 | Roche cobas | 1,880,000 IU/mL | 28-Sep-16 | Lightpower HCV Genotype Rt-PCR | 1 | 3-Oct-16 | $200.00 | Unknown | Decreased appetite | Yes | No | Unknown | ALT: 143 U/L; AST: 176 U/L; Bilirubin: 13.8 umol/L; Serum Creatinine: 72 umol/L 22-Sep-16 | N/A | N/A | ||||||||||
| BBS0005-CV900056186092716DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 19.00 | $200.00 | 33 Y | Male | Non-Hispanic | <-70C | 27-Sep-16 | Roche cobas | 338,000 IU/mL | 23-Sep-16 | Lightpower HCV Genotype Rt-PCR | 1 | 29-Sep-16 | $200.00 | Unknown | Decreased appetite; Fatigue; Itching | No | No | Transfusion | ALT: 76 U/L; AST: 345 U/L; Bilirubin: 10.2 umol/L; Serum Creatinine: 1153 umol/L 20-Sep-16 | N/A | N/A | ||||||||||
| BBS0005-CV900056780110415DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 16.00 | $200.00 | 39 Y | Male | Non-Hispanic | <-70C | 04-Nov-15 | Lightpower HCV Genotype Rt-PCR | 1 | 11-Nov-15 | $200.00 | Unknown | Fatigue; Nausea; GI bleeding | |||||||||||||||||||
| BBS0005-CV900056784100115DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 69 Y | Female | Non-Hispanic | <-70C | 01-Oct-15 | Roche cobas | 1,680,000 IU/mL | 30-Sep-15 | Lightpower HCV Genotype Rt-PCR | 1 | 8-Oct-15 | $200.00 | Unknown | Decreased appetite; Fatigue | ||||||||||||||||
| BBS0005-CV900057163072214DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 59 Y | Female | Non-Hispanic | < -70C | 22-Jul-14 | Roche HCV Monitor | 4,960,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Jaundice | No | No | Unknown | ALT: 104; AST: 52; Bilirubin: 11 umol/L; Serum Creatinine: 0.8 mg/dL | ||||||||||||||
| BBS0005-CV900057165042214DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 33 Y | Male | Non-Hispanic | < -70C | 22-Apr-14 | Roche cobas | 9,020,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain; Sleep disturbances | No | No | Unknown | |||||||||||||||
| BBS0005-CV900057167061314DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 5.00 | $200.00 | 37 Y | Male | Non-Hispanic | < -70C | 13-Jun-14 | Roche cobas | 10,600,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Sexual Transmission; IV Drug Abuse | ALT: 71; AST: 52; Serum Creatinine: 92 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2003 | ||||||||||||
| BBS0005-CV900057168061214DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 7.00 | $200.00 | 35 Y | Male | Non-Hispanic | < -70C | 12-Jun-14 | Roche cobas | 25,200,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | IV Drug Abuse | ALT: 103; AST: 113 | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2011 | ||||||||||||
| BBS0005-CV900057169051414DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 8.00 | $200.00 | 43 Y | Male | Non-Hispanic | < -70C | 14-May-14 | Roche cobas | 12,700 copies/mL | 6-May-14 | Lightpower HCV Genotype Rt-PCR | 1 | 22-May-14 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Sexual Transmission; IV Drug Abuse | ALT: 52; AST: 51; Serum Creatinine: 98 umol/L 3-Apr-14 | HBsAg +; Anti HCV + (Elisa) 2-Apr-13 | HIV+ 2-Apr-13 | ||||||||||
| BBS0005-CV900057170061314DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 67 Y | Male | Non-Hispanic | < -70C | 13-Jun-14 | Roche HCV Monitor | 1,510,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Fatigue; Abdominal pain; Sleep disturbances | No | No | Unknown | ALT: 66; AST: 103; ALP: 102; Bilirubin: 15.3 umol/L; Serum Creatinine: 0.67 mg/dL | Anti HCV+ (Elisa) | None | ||||||||||||
| BBS0005-CV900060032072213DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 40 Y | Male | Non-Hispanic | < -70C | 22-Jul-13 | Roche cobas | 16,200,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Fatigue | Yes | Yes Zidovudine 300 mg; Lamivudine 150 mg;Nevirapine 200 mg | IV Drug Abuse | ALT: 47 U/L; AST: 24 U/L; Serum Creatinine: 76 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2007 | ||||||||||||
| BBS0005-CV900060034061413DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 5.00 | $200.00 | 31 Y | Male | Non-Hispanic | < -70C | 14-Jun-13 | Roche cobas | 4,200,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 33; AST: 19; Bilirubin: 4.7 umol/L | ||||||||||||||
| BBS0005-CV900061269011315DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 31 Y | Male | Non-Hispanic | < -70C | 13-Jan-15 | Roche cobas | 5,920,000 copies/mL | 6-Jan-15 | Lightpower HCV Genotype Rt-PCR | 1 | 21-Jan-15 | $200.00 | Unknown | No symptoms | No | No None | Sexual Transmission | ALT: 89 U/L; AST: 38 U/L; Serum Creatinine: 89 umol/L 6-Jan-15 | HBsAg -; Anti HCV + (Elisa) 6-Jan-15 | |||||||||||
| BBS0005-CV900061272092514DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 64 Y | Male | Non-Hispanic | < -70C | 25-Sep-14 | Roche cobas | 17,300 IU/mL | 24-Sep-14 | Lightpower HCV Genotype Rt-PCR | 1 | 13-Oct-14 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 77 U/L; AST: 58 U/L; Bilirubin: 7.8 umol/L; Serum Creatinine: 1.0 mg/dL 10-Sep-14 | ||||||||||||
| BBS0005-CV900061273101314DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 35 Y | Male | Non-Hispanic | < -70C | 13-Oct-14 | Roche cobas | 40,800 IU/mL | 25-Sep-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Oct-14 | $200.00 | Unknown | Decreased appetite; Fatigue; Sleep disturbances | No | No | Unknown | ALT: 61 U/L; AST: 78 U/L; Bilirubin: 9.8 umol/L; Serum Creatinine: 0.9 mg/dL 3-Oct-14 | ||||||||||||
| BBS0005-CV900062423112213DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 4.00 | $200.00 | 39 Y | Male | Non-Hispanic | < -70C | 22-Nov-13 | Roche cobas | 2,090,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Sexual Transmission; IV Drug Abuse | ALT: 67 U/L; AST: 33 U/L; Serum Creatinine: 86 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2008 | ||||||||||||
| BBS0005-CV900062426121913DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 7.00 | $200.00 | 37 Y | Male | Non-Hispanic | < -70C | 19-Dec-13 | Roche cobas | 58,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 98 U/L; AST: 48 U/L; Bilirubin: 7.7 umol/L; Serum Creatinine: 89 umol/L | HBsAg-; Anti HCV+ (ECLIA Cobas 6000) | |||||||||||||
| BBS0005-CV900063246110116DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 35 Y | Male | Non-Hispanic | <-70C | 01-Nov-16 | Roche cobas | 837,000 IU/mL | 26-Oct-16 | Lightpower HCV Genotype Rt-PCR | 1 | 3-Nov-16 | $200.00 | Unknown | Decreased appetite; Fatigue; Sleep disturbances | No | No | Unknown | ALT: 186 U/L; AST: 602 U/L; Bilirubin: 82.5 umol/L; Serum Creatinine: 74 umol/L 31-Oct-16 | HCV Ab + (cobas 6000E) 16-Oct | N/A | ||||||||||
| BBS0005-CV900063248102516DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 54 Y | Female | Non-Hispanic | <-70C | 25-Oct-16 | Roche cobas | 195,000 IU/mL | 24-Oct-16 | Lightpower HCV Genotype Rt-PCR | 1 | 29-Oct-16 | $200.00 | Unknown | Decreased appetite; Abdominal pain; Itching | No | No | Unknown | ALT: 84 U/L; AST: 168 U/L; Bilirubin: 16.2 umol/L; Serum Creatinine: 74 umol/L 5-Oct-16 | HCV Ab + (cobas 6000E) 5-Oct-16 | N/A | ||||||||||
| BBS0005-CV900063251101316DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 15.00 | $200.00 | 48 Y | Female | Non-Hispanic | <-70C | 13-Oct-16 | Roche cobas | 9,800 IU/mL | 11-Oct-16 | Lightpower HCV Genotype Rt-PCR | 1 | 17-Oct-16 | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain | No | No | Unknown | ALT: 34 U/L; AST: 47 U/L; Bilirubin: 12.1 umol/L; Serum Creatinine: 68 umol/L 6-Oct-16 | N/A | N/A | ||||||||||
| BBS0005-CV900063263092316DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 42 Y | Male | Non-Hispanic | <-70C | 23-Sep-16 | Roche cobas | 6,800 IU/mL | 23-Sep-16 | Lightpower HCV Genotype Rt-PCR | 1 | 29-Sep-16 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | IV Drug Abuse | ALT: 166 U/L; AST: 276 U/L; Bilirubin: 55.1 umol/L; Serum Creatinine: 77 umol/L 21-Sep-16 | N/A | HIV+ 2006 | ||||||||||
| BBS0005-CV900063264100616DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 40 Y | Male | Non-Hispanic | <-70C | 06-Oct-16 | Roche cobas | 1,460,000 IU/mL | 4-Oct-16 | Lightpower HCV Genotype Rt-PCR | 1 | 10-Oct-16 | $200.00 | Unknown | Decreased appetite; Fatigue | Yes | No | Unknown | ALT: 39 U/L; AST: 86 U/L; Serum Creatinine: 76 umol/L 28-Sep-16 | N/A | N/A | ||||||||||
| BBS0005-CV900063265092716DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 20.00 | $200.00 | 61 Y | Male | Non-Hispanic | <-70C | 27-Sep-16 | Roche cobas | 217,000 IU/mL | 26-Sep-16 | Lightpower HCV Genotype Rt-PCR | 1 | 29-Sep-16 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 45 U/L; AST: 5 U/L; 42621; Serum Creatinine: 172 umol/L 23-Sep-16 | N/A | N/A | ||||||||||
| BBS0005-CV900063322121515DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 15.00 | $200.00 | 33 Y | Male | Non-Hispanic | <-70C | 15-Dec-15 | Lightpower HCV Genotype Rt-PCR | 1 | 16-Dec-15 | $200.00 | Unknown | No symptoms | HIV Positive 13-Oct-15 | ||||||||||||||||||
| BBS0005-CV900063329090115DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 3.00 | $200.00 | 29 Y | Male | Non-Hispanic | <-70C | 01-Sep-15 | Roche cobas | 11,300,000 IU/mL | 20-Aug-15 | Lightpower HCV Genotype Rt-PCR | 1 | 3-Sep-15 | $200.00 | Unknown | Fatigue | No | No | IV Drug Abuse | |||||||||||||
| BBS0005-CV900063330102615DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 43 Y | Male | Non-Hispanic | <-70C | 26-Oct-15 | Roche cobas | 5,720,000 IU/mL | 9-Oct-15 | Lightpower HCV Genotype Rt-PCR | 1 | 5-Nov-15 | $200.00 | Unknown | Decreased appetite; Fatigue | HIV Positive 8-Feb-10 | |||||||||||||||
| BBS0005-CV900064084092414DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 15.00 | $200.00 | 49 Y | Female | Non-Hispanic | < -70C | 24-Sep-14 | Roche cobas | 1,800,000 IU/mL | 17-Sep-14 | Lightpower HCV Genotype Rt-PCR | 1 | 13-Oct-14 | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain | No | No | Unknown | ALT: 176; AST: 162; Bilirubin: 15.3 umol/L; Serum Creatinine: 0.7 mg/dL 22-Sep-14 | ||||||||||||
| BBS0005-CV900064085073114DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 16.00 | $200.00 | 41 Y | Male | Non-Hispanic | < -70C | 31-Jul-14 | Roche cobas | 53,300 IU/mL | 25-Jun-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Oct-14 | $200.00 | Unknown | Fatigue; Jaundice | No | No | Unknown | HBsAg +; Anti HCV + (Elisa) 20-Jun-14 | ||||||||||||
| BBS0005-CV900066334052813DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 5.00 | $200.00 | 59 Y | Female | Non-Hispanic | <-70°C | 28-May-13 | Roche cobas | 24,000,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Sleep disturbances; Nausea | No | No | Unknown | ALT: 12; AST: 50; Bilirubin: 10.8 umol/L; Serum Creatinine: 98 umol/L; Hepatitis C | ||||||||||||||
| BBS0005-CV900066341101615DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 8.00 | $200.00 | 25 Y | Male | Non-Hispanic | <-70C | 16-Oct-15 | Roche cobas | 412,000 IU/mL | 28-Sep-15 | Lightpower HCV Genotype Rt-PCR | 1 | 19-Nov-15 | $200.00 | Unknown | No symptoms | HIV Positive 18-Apr-14 | |||||||||||||||
| BBS0005-CV900066348090715DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 56 Y | Male | Non-Hispanic | <-70C | 07-Sep-15 | Roche cobas | 5,990 copies/mL | 1-Sep-15 | Lightpower HCV Genotype Rt-PCR | 1 | 10-Sep-15 | $200.00 | Unknown | Fatigue | No | No | Unknown | |||||||||||||
| BBS0005-CV900066349091815DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 29 Y | Male | Non-Hispanic | <-70C | 18-Sep-15 | Lightpower HCV Genotype Rt-PCR | 1 | 24-Sep-15 | $200.00 | Unknown | No symptoms | HIV Positive 5-Jul-13 | ||||||||||||||||||
| BBS0005-CV900067324120314DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 37 Y | Male | Non-Hispanic | < -70C | 03-Dec-14 | Roche cobas | 712,000 copies/mL | 30-Oct-14 | Lightpower HCV Genotype Rt-PCR | 1 | 4-Dec-14 | $200.00 | Unknown | Decreased Appetite; Fatigue | No | Yes Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Unknown | ALT: 30 U/L; AST: 100 U/L; Serum Creatinine: 99 umol/L 26-Jun-14 | HBsAG -; Anti HCV + (Elisa) 6-Dec-12 | |||||||||||
| BBS0005-CV900067325040215DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 4.00 | $200.00 | 48 Y | Male | Non-Hispanic | <-70C | 02-Apr-15 | Roche cobas | 69,000,000 IU/mL | 27-Mar-15 | Lightpower HCV Genotype Rt-PCR | 1 | 8-Apr-15 | $200.00 | Unknown | Fatigue; Jaundice | Partial | No | Unknown | ALT: 827 U/L; AST: 320 U/L; Bilirubin: 299 umol/L; Serum Creatinine: 79 umol/L 31-Mar-15 | None | |||||||||||
| BBS0005-CV900067333051415DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 41 Y | Male | Non-Hispanic | <-70C | 14-May-15 | Roche cobas | 888,000 IU/mL | 6-Mar-15 | Lightpower HCV Genotype Rt-PCR | 1 | 21-May-15 | $200.00 | Unknown | No symptoms | No | No | Unknown | |||||||||||||
| BBS0005-CV900067685101316DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 43 Y | Male | Non-Hispanic | <-70C | 13-Oct-16 | Roche cobas | 178,000 IU/mL | 11-Oct-16 | Lightpower HCV Genotype Rt-PCR | 1 | 17-Oct-16 | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain | No | No | Unknown | ALT: 121 U/L; AST: 133 U/L; Bilirubin: 9.4 umol/L; Serum Creatinine: 97 umol/L 6-Oct-16 | N/A | N/A | ||||||||||
| BBS0005-CV900067686110816DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 15.00 | $200.00 | 44 Y | Female | Non-Hispanic | <-70C | 08-Nov-16 | Roche cobas | 21,200 IU/mL | 2-Nov-16 | Lightpower HCV Genotype Rt-PCR | 1 | 10-Nov-16 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 41 U/L; AST: 65 U/L; Bilirubin: 11.5 umol/L; Serum Creatinine: 63 umol/L 28-Oct-16 | N/A | N/A | ||||||||||
| BBS0005-CV900067698062317DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 17.00 | $200.00 | 32 Y | Female | Non-Hispanic | <-70C | 23-Jun-17 | Roche Cobas | 260,000 IU/mL | 23-Jun-17 | Lightpower HCV Genotype Rt-PCR | 1 | 20-Jun-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | Abdominal pain; Fatigue | None | U/A | ALT: 48 U/L | AST: 82 U/L | Bilirubin: 28 umol/L | Serum Creatinine: 62 umol/L 20-Jun-17 | None | None | |||||||||
| BBS0005-CV900067699112116DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 15.00 | $200.00 | 30 Y | Male | Non-Hispanic | <-70C | 21-Nov-16 | Roche HCV Monitor | 11,300,000 copies/mL | 15-Nov-16 | Lightpower HCV Genotype Rt-PCR | 1 | 22-Nov-16 | $200.00 | Unknown | No symptoms | Yes | Yes Tenofovir; Lamivudine; Efavirenz | Sexual transmission | ALT: 68 U/L; AST: 110 U/L; Serum Creatinine: 90 umol/L 13-Oct-16 | N/A | HIV+ 12-Apr-16 | ||||||||||
| BBS0005-CV900067701011817DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 8.00 | $200.00 | 40 Y | Male | Non-Hispanic | <-70C | 18-Jan-17 | Roche Cobas | 10,400,000 IU/mL | 16-Jan-17 | $200.00 | Unknown | Fatigue | No | No None | Unknown | ALT: 54 U/L, AST: 27 U/L, Bilirubin: 62 umol/L, Serum Creatinine: 74 umol/L 17-Jan-17 | None | None | |||||||||||||
| BBS0005-CV900067703113016DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 58 Y | Male | Non-Hispanic | <-70C | 30-Nov-16 | Roche cobas | 270,000 IU/mL | 28-Nov-16 | Lightpower HCV Genotype Rt-PCR | 1 | 1-Dec-16 | $200.00 | Unknown | Fatigue; Abdominal pain | No | No | Unknown | ALT: 85 U/L; AST: 88 U/L; Bilirubin: 49.2 umol/L; Serum Creatinine: 83 umol/L 27-Nov-16 | HCV Ab + (cobas 6000E) 21-Nov-16 | N/A | ||||||||||
| BBS0005-CV900067720040517DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 8.00 | $200.00 | 48 Y | Male | Non-Hispanic | <-70C | 05-Apr-17 | Roche Cobas | 590,000 IU/mL | 2-Apr-17 | $200.00 | Unknown | Decreased appetite; Depression; Fatigue; Jaundice | No | No None | Unknown | ALT: 101 U/LAST: 173 U/L Bilirubin: 12.6 umol/LSerum Creatinine: 89 umol/LChronic HCV Mar-2017 29-Mar-17 | HCV Ab + | None | |||||||||||||
| BBS0005-CV900067722111716DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 35 Y | Male | Non-Hispanic | <-70C | 17-Nov-16 | Roche HCV Monitor | 2,990,000 copies/mL | 15-Nov-16 | Lightpower HCV Genotype Rt-PCR | 1 | 18-Nov-16 | $200.00 | Unknown | No symptoms | No | No | IV Drug Abuse | ALT: 59 U/L; AST: 57 U/L; Serum Creatinine: 94 umol/L; Biopsy Result: (F1; 8-Mar-2016) 13-Sep-16 | N/A | HIV+ 10-Feb-16 | ||||||||||
| BBS0005-CV900068563120915DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 7.00 | $200.00 | 66 Y | Male | Non-Hispanic | <-70C | 09-Dec-15 | Roche cobas | 1,820,000 IU/mL | 3-Dec-15 | Lightpower HCV Genotype Rt-PCR | 1 | 16-Dec-15 | $200.00 | Unknown | Fatigue; Abdominal pain | ||||||||||||||||
| BBS0005-CV900068567081815DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 43 Y | Female | Non-Hispanic | <-70C | 18-Aug-15 | Roche cobas | 16,700,000 IU/mL | 6-Aug-15 | Lightpower HCV Genotype Rt-PCR | 1 | 20-Aug-15 | $200.00 | Unknown | Fatigue; Nausea | No | No | Unknown | |||||||||||||
| BBS0005-CV900068568090115DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 57 Y | Female | Non-Hispanic | <-70C | 01-Sep-15 | Roche cobas | 14,900,000 IU/mL | 19-Aug-15 | Lightpower HCV Genotype Rt-PCR | 1 | 3-Sep-15 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | |||||||||||||
| BBS0005-CV900069475081814DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 33 Y | Female | Non-Hispanic | < -70C | 18-Aug-14 | Roche cobas | 441,000 IU/mL | 7-Aug-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Oct-14 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 21; AST: 23; Bilirubin: 8.1 umol/L; Serum Creatinine: 0.67 mg/dL 7-Aug-14 | ||||||||||||
| BBS0005-CV900069478100214DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 45 Y | Male | Non-Hispanic | < -70C | 02-Oct-14 | Roche cobas | 13,700,000 copies/mL | 11-Sep-14 | Lightpower HCV Genotype Rt-PCR | 1 | 13-Oct-14 | $200.00 | Unknown | Fatigue; Abdominal pain | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | IV Drug Abuse | ALT: 44; AST: 81 3-Sep-14 | HBsAg -; Anti HCV + (Elisa) 10-Jan-07 | HIV+ 15-Jun-06 | ||||||||||
| BBS0005-CV900069482071014DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 52 Y | Female | Non-Hispanic | < -70C | 10-Jul-14 | Roche HCV Monitor | 2,850,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain; Jaundice | No | No | Unknown | ALT: 343; AST: 610; Bilirubin: 95.8 umol/L; Serum Creatinine: 0.66 mg/dL | ||||||||||||||
| BBS0005-CV900069483050614DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 2.00 | $200.00 | 64 Y | Female | Non-Hispanic | < -70C | 06-May-14 | Roche cobas | 2,700,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Itching; Sleep disturbances; Depression | No | No | Unknown | ALT: 160; AST: 72; Serum Creatinine: 0.6 mg/dL | ||||||||||||||
| BBS0005-CV900071670122216DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 37 Y | Male | Non-Hispanic | <-70C | 22-Dec-16 | Roche Cobas | 210,000 IU/mL | 21-Dec-16 | $200.00 | Unknown | Fatigue; Abdominal pain | No | Yes Tenofovir; Lamivudine; Efavirenz | IV Drug Abuse | ALT: 43 U/, LAST: 24 U/L, Serum Creatinine: 87 umol/L, HCV 2010 20-Dec-16 | None | HIV+ 19-Aug-10 | |||||||||||||
| BBS0005-CV900071671120916DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 8.00 | $200.00 | 67 Y | Male | Non-Hispanic | <-70C | 09-Dec-16 | Roche Cobas | 162,000 IU/mL | 8-Dec-16 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No None | Unknown | ALT: 72 U/L, AST: 84 U/L, Bilirubin: 19 umol/L, Serum Creatinine: 63 umol/L, Chronic HCV 2015 6-Dec-16 | None | None | |||||||||||||
| BBS0005-CV900071672022017DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 41 Y | Male | Non-Hispanic | <-70C | 20-Feb-17 | Roche Cobas | 23,000,000 IU/mL | 18-Feb-17 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No None | Unknown | ALT: 32.8 U/L, AST: 24.2 U/L, Serum Creatinine: 77.2 umol/L, Chronic HCV 2015 7-Feb-17 | HCV Ab + | None | |||||||||||||
| BBS0005-CV900071675121616DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 52 Y | Male | Non-Hispanic | <-70C | 16-Dec-16 | Roche Cobas | 170,000 IU/mL | 15-Dec-16 | $200.00 | Unknown | Fatigue | No | No None | Unknown | ALT: 82 U/L, AST: 63 U/L, Chronic HCV 2015 15-Dec-16 | None | None | |||||||||||||
| BBS0005-CV900071677120816DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 42 Y | Male | Non-Hispanic | <-70C | 08-Dec-16 | Roche Cobas | 30,600,000 copies/mL | 6-Dec-16 | $200.00 | Unknown | Fatigue | No | Yes Tenofovir; Lamivudine; Efavirenz | Sexual Transmission | ALT: 12 U/L, AST: 46 U/L, Serum Creatinine: 128 umol/L 26-Sep-16 | None | HIV+ 15-Oct-10 | |||||||||||||
| BBS0005-CV900072421072115DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 61 Y | Female | Non-Hispanic | <-70C | 21-Jul-15 | Roche cobas | 5,690,000 IU/mL | 16-Jul-15 | Lightpower HCV Genotype Rt-PCR | 1 | 7-Aug-15 | $200.00 | Unknown | Fatigue | No | No | Unknown | |||||||||||||
| BBS0005-CV900072423090815DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 65 Y | Female | Non-Hispanic | <-70C | 08-Sep-15 | Roche cobas | 8,950,000 IU/mL | 4-Sep-15 | Lightpower HCV Genotype Rt-PCR | 1 | 10-Sep-15 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | |||||||||||||
| BBS0005-CV900072425090715DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 36 Y | Male | Non-Hispanic | <-70C | 07-Sep-15 | Roche cobas | 9,000,000 copies/mL | 3-Jul-15 | Lightpower HCV Genotype Rt-PCR | 1 | 10-Sep-15 | $200.00 | Unknown | Fatigue | No | No | IV Drug Abuse | |||||||||||||
| BBS0005-CV900074811082514DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 37 Y | Female | Non-Hispanic | < -70C | 25-Aug-14 | Roche cobas | 2,900 IU/mL | 19-Aug-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Oct-14 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 19; AST: 14 19-Aug-14 | Anti HCV + (Elisa) 28-Aug-14 | |||||||||||
| BBS0005-CV900074812050514DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 45 Y | Male | Non-Hispanic | < -70C | 05-May-14 | Roche cobas | 1,810,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | No symptoms | No | Yes Abcarvir 300 mg Lamivudine 150 mg Efavirenz 600 mg | Sexual Transmission; IV Drug Abuse | ALT: 51; AST: 66; Serum Creatinine: 131 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2002 | ||||||||||||
| BBS0005-CV900074814052114DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 4.00 | $200.00 | 49 Y | Male | Non-Hispanic | < -70C | 21-May-14 | Roche cobas | 15,500,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | IV Drug Abuse | ALT: 44; AST: 36; Serum Creatinine: 75 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2009 | ||||||||||||
| BBS0005-CV900074815061114DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 3.00 | $200.00 | 32 Y | Male | Non-Hispanic | < -70C | 11-Jun-14 | Roche cobas | 2,140,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | No symptoms | Yes | Yes Tenofovir 300 mg; Lamivudine 150 mg; Aluvia 200/50 mg | IV Drug Abuse | ALT: 58; AST: 49; Serum Creatinine: 94 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 1999 | ||||||||||||
| BBS0005-CV900076255031417DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 39 Y | Female | Non-Hispanic | <-70C | 14-Mar-17 | Roche Cobas | 7,640,000 IU/mL | 10-Mar-17 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No None | Unknown | ALT: 535 U/L, AST: 1173 U/L, Bilirubin: 53.4 umol/L, Serum Creatinine: 70 umol/L, HCV 2017 13-Mar-17 | HCV Ab + | None | |||||||||||||
| BBS0005-CV900076258111416DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 7.00 | $200.00 | 34 Y | Male | Non-Hispanic | <-70C | 14-Nov-16 | Roche HCV Monitor | 44,000,000 copies/mL | 25-Nov-16 | Lightpower HCV Genotype Rt-PCR | 1 | 16-Nov-16 | $200.00 | Unknown | Fatigue | No | No | IV Drug Abuse | ALT: 14 U/L; AST: 29 U/L; Serum Creatinine: 87 umol/L 13-Oct-16 | N/A | HIV+ 13-Oct-15 | ||||||||||
| BBS0005-CV900077145030215DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 7.00 | $200.00 | 38 Y | Male | Non-Hispanic | <-70C | 02-Mar-15 | Roche cobas | 82,500 copies/mL | 5-Nov-14 | Lightpower HCV Genotype Rt-PCR | 1 | 13-Mar-15 | $200.00 | Unknown | Fatigue; Abdominal Pain | Yes | Yes | IV Drug Abuse | ALT: 66 U/L; AST: 87 U/L 27-Oct-14 | HBsAg -; Anti HCV + (Elisa) 15-Mar-11 | |||||||||||
| BBS0005-CV900077235072014DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 7.00 | $200.00 | 36 Y | Male | Non-Hispanic | < -70C | 20-Jul-14 | Roche cobas | 3,360,000 IU/mL | 16-Jul-14 | Lightpower HCV Genotype Rt-PCR | 1 | 14-Oct-14 | $200.00 | Unknown | No symptoms | No | No | IV Drug Abuse | HBsAg -; Anti HCV + (Elisa) 16-Jul-14 | ||||||||||||
| BBS0005-CV900078362051817DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 39 Y | Male | Non-Hispanic | <-70C | 18-May-17 | Roche Cobas | 3,260,000 IU/mL | 18-May-17 | Lightpower HCV Genotype Rt-PCR | 1 | 25-May-17 | 3-series HepB Vaccine | no | $200.00 | Unknown | Decreased appetite; Abdominal pain; Night sweats; Dark urine; Fatigue; Sleep disturbances | None | U/A | ALT: 52 U/L | AST: 37 U/L | Serum Creatinine: 74 umol/L 12-May-17 | HCV Ab + | COBAS 6000E 12-May-17 | None | |||||||||
| BBS0005-CV900078363022317DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 8.00 | $200.00 | 34 Y | Male | Non-Hispanic | <-70C | 23-Feb-17 | Roche Cobas | 910,000 IU/mL | 21-Feb-17 | $200.00 | Unknown | Fatigue | No | Yes Tenofovir; Lamivudine; Efavirenz | IV Drug Abuse | ALT: 61 U/L, AST: 41 U/L, Bilirubin: 45 umol/L, Serum Creatinine: 74 umol/L, Chronic HCV 2014 20-Feb-17 | None | HIV+ 17-Jul-14 | |||||||||||||
| BBS0005-CV900078364041217DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 46 Y | Female | Non-Hispanic | <-70C | 12-Apr-17 | Roche Cobas | 26,000,000 IU/mL | 12-Apr-17 | $200.00 | Unknown | Jaundice; Fatigue; Abdominal pain | No | No None | Unknown | ALT: 1276 U/L, AST: 98 U/L, Bilirubin: 127 umol/L, Serum Creatinine: 82 umol/L, HCV 9-Apr-2017 10-Apr-17 | HCV Ab + | None | |||||||||||||
| BBS0005-CV900078375111516DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 8.00 | $200.00 | 38 Y | Male | Non-Hispanic | <-70C | 15-Nov-16 | Roche HCV Monitor | 2,060,000 copies/mL | 13-Nov-16 | Lightpower HCV Genotype Rt-PCR | 1 | 16-Nov-16 | $200.00 | Unknown | Fatigue | No | No | IV Drug Abuse | ALT: 111 U/L; AST: 65 U/L; Serum Creatinine: 82 umol/L; Biopsy Result: (F1 (6 kPa); 25-Dec-2014) 14-Sep-16 | N/A | HIV+ 31-Dec-14 | ||||||||||
| BBS0005-CV900081399112116DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 43 Y | Male | Non-Hispanic | <-70C | 21-Nov-16 | Roche cobas | 7,710,000 copies/mL | 20-Nov-16 | Lightpower HCV Genotype Rt-PCR | 1 | 22-Nov-16 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir; Lamivudine; Efavirenz | IV Drug Abuse | ALT: 71 U/L; AST: 55 U/L; Serum Creatinine: 92 umol/L 19-May-16 | N/A | HIV+ 10-Aug-10 | ||||||||||
| BBS0005-CV900081401011217DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 38 Y | Male | Non-Hispanic | <-70C | 12-Jan-17 | Roche Cobas | 1,560,000 copies/mL | 10-Jan-17 | $200.00 | Unknown | Fatigue | Partial | Yes Tenofovir; Lamivudine; Efavirenz | IV Drug Abuse | ALT: 47 U/L, AST: 157 U/L, Serum Creatinine: 87 umol/L 27-Sep-16 | None | HIV+ 9-Oct-10 | |||||||||||||
| BBS0005-CV900081402123016DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 15.00 | $200.00 | 43 Y | Female | Non-Hispanic | <-70C | 30-Dec-16 | Roche Cobas | 83,700 IU/mL | 29-Dec-16 | $200.00 | Unknown | Decreased appetite; Abdominal pain | Yes | No None | Unknown | ALT: 89 U/L, AST: 123 U/L, Bilirubin: 17.3 umol/L, Serum Creatinine: 74 umol/L, HCV 2014 22-Dec-16 | None | None | |||||||||||||
| BBS0005-CV900081403042717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 16.00 | $200.00 | 57 Y | Male | Non-Hispanic | <-70C | 27-Apr-17 | Roche Cobas | 6,690 IU/mL | 27-Apr-17 | Lightpower HCV Genotype Rt-PCR | 1 | 28-Apr-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | Fatigue; Jaundice | None | U/A | ALT: 91 U/L | AST: 90 U/L | Bilirubin: 22 umol/L | Serum Creatinine: 73 umol/L 26-Apr-17 | None | None | |||||||||
| BBS0005-CV900081404042717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 5.00 | $200.00 | 35 Y | Male | Non-Hispanic | <-70C | 27-Apr-17 | Roche Cobas | 2,050,000 IU/mL | 27-Apr-17 | Lightpower HCV Genotype Rt-PCR | 1 | 28-Apr-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | Itching; Unexplained weight loss; Fatigue | None | IV Drug Abuse | ALT: 32 U/L | AST: 45 U/L | Bilirubin: 21 umol/L | Serum Creatinine: 73 umol/L 22-Apr-17 | None | None | |||||||||
| BBS0005-CV900081405042617DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 15.00 | $200.00 | 57 Y | Male | Non-Hispanic | <-70C | 26-Apr-17 | Roche Cobas | 736,000 IU/mL | 26-Apr-17 | Lightpower HCV Genotype Rt-PCR | 1 | 28-Apr-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | Fatigue | None | U/A | ALT: 72 U/L | AST: 64 U/L | Bilirubin: 62 umol/L | Serum Creatinine: 54 umol/L 25-Apr-17 | HCV Ab + | COBAS 6000E 3-Jul-05 | None | |||||||||
| BBS0005-CV900081417051017DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 18.00 | $200.00 | 63 Y | Male | Non-Hispanic | <-70C | 10-May-17 | Roche Cobas | 30,300,000 IU/mL | 10-May-17 | Lightpower HCV Genotype Rt-PCR | 1 | 15-May-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | Fatigue; Jaundice | None | U/A | ALT: 111 U/L | AST: 214 U/L | Bilirubin: 18.4 umol/L | Serum Creatinine: 78 umol/L 5-May-17 | HCV Ab + | COBAS 6000E 4-May-17 | None | |||||||||
| BBS0005-CV900087491052217DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 43 Y | Male | Non-Hispanic | <-70C | 22-May-17 | Roche Cobas | 11,600,000 IU/mL | 22-May-17 | Lightpower HCV Genotype Rt-PCR | 1 | 25-May-17 | 3-series HepB Vaccine | Yes | $200.00 | Unknown | Fatigue; Jaundice | None | IV Drug Abuse | ALT: 45 U/L | AST: 34 U/L | Serum Creatinine: 114 umol/L 8-May-17 | None | None | |||||||||
| BBS0005-CV900087493052217DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 38 Y | Male | Non-Hispanic | <-70C | 22-May-17 | Roche Cobas | 5,000,000 IU/mL | 22-May-17 | Lightpower HCV Genotype Rt-PCR | 1 | 25-May-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | Itching; Night sweats; Unexplained weight loss; Fatigue; Flu-like symptoms | None | U/A | ALT: 26 U/L | AST: 37 U/L | Bilirubin: 12 umol/L | Serum Creatinine: 73 umol/L 12-May-17 | None | None | |||||||||
| BBS0005-CV900087494042617DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 16.00 | $200.00 | 60 Y | Male | Non-Hispanic | <-70°C | 26-Apr-17 | Roche Cobas | 2,990,000 IU/mL | 26-Apr-17 | Real Time PCR | Genotype 1 | 28-Apr-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | Fatigue; Jaundice | No | U/A | ALT: 62 U/L | AST: 78 U/L | Bilirubin: 62 umol/L | Serum Creatinine: 60 umol/L 20-Apr-17 | HCV Ab + 27-Apr-17 | None | |||||||||
| BBS0005-CV900087496020717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 28 Y | Male | Non-Hispanic | <-70C | 07-Feb-17 | Roche Cobas | 21,100,000 IU/mL | 5-Feb-17 | $200.00 | Unknown | Fatigue; Abdominal pain | No | No None | Unknown | ALT: 128 U/L, AST: 138 U/L, Bilirubin: 21.4 umol/L, Serum Creatinine: 54 umol/L, HCV 2017 5-Feb-17 | None | None | |||||||||||||
| BBS0005-CV900087508030817DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 44 Y | Male | Non-Hispanic | <-70C | 08-Mar-17 | Roche Cobas | 2,060,000 copies/mL | 6-Mar-17 | $200.00 | Unknown | Fatigue | No | Yes Tenofovir; Lamivudine; Efavirenz | Sexual Transmission | ALT: 69 U/L, AST: 120 U/L , Serum Creatinine: 103 umol/L 26-Dec-16 | None | HIV+ 12-Nov-12 | |||||||||||||
| BBS0005-CV900089036051517DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 35 Y | Male | Non-Hispanic | <-70C | 15-May-17 | Roche Cobas | 50,100 IU/mL | 25-May-17 | Lightpower HCV Genotype Rt-PCR | 1 | 23-May-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain; Itching; Sleep disturbances | None | U/A | ALT: 36 U/L | AST: 52 U/L | Bilirubin: 12 umol/L | Serum Creatinine: 76 umol/L 4-May-17 | HCV Ab + | COBAS 6000E | None | |||||||||
| BBS0005-CV900089041062217DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 47 Y | Male | Non-Hispanic | <-70C | 22-Jun-17 | Roche Cobas | 5,000,000 IU/mL | 22-Jun-17 | Lightpower HCV Genotype Rt-PCR | 1 | 26-Jun-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | Fatigue; Jaundice | None | U/A | ALT: 68 U/L | AST: 72 U/L 22-Jun-17 | HCV Ab + | COBAS 6000E 18-Jun-17 | None | |||||||||
| BBS0005-EN900023460040918DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 70 Y | Female | Non-Hispanic | <-70C | 09-Apr-18 | Roche cobas | 1,000,000 IU/mL | HCV Viral Load | Genotype | 1b | 21-Nov-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | ALT: 36.4 U/L | AST: 34.5 U/L | Bilirubin: 0.95 mg/dL | Creatinine: 0.65 mg/dL | Chronic Hepatitis C 21-Mar-18 | HBsAg- | HBsAb- | HBcAb- | (CMIA) 21-Mar-18 | None | |||||||||
| BBS0005-EN900023461041318DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 70 Y | Male | Non-Hispanic | <-70C | 13-Apr-18 | Roche cobas | 290,000 IU/mL | HCV Viral Load | Genotype | 1b | 13-Sep-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | Bilirubin: 0.7 mg/dL | Creatinine: 0.9 mg/dL | Chronic Hepatitis C 26-Mar-18 | HBsAg- | HBsAb- | HBcAb- | (CMIA) 6-Apr-18 | None | |||||||||
| BBS0005-EN900023462041818DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 57 Y | Male | Non-Hispanic | <-70C | 18-Apr-18 | Roche cobas | 212 IU/mL | HCV Viral Load | Genotype | 1a | 5-Jun-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | Bilirubin: 0.78 mg/dL | Creatinine: 1.0 mg/dL | Chronic Hepatitis C 9-Apr-18 | HBsAg- | HBsAb+ | 6-Nov- (CMIA) 2017 | None | |||||||||
| BBS0005-EN900023463042718DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 70 Y | Female | Non-Hispanic | <-70C | 27-Apr-18 | Roche cobas | 9,550,000 IU/mL | HCV Viral Load | Genotype | 1a | 15-Jan-18 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | Bilirubin: 0.7 mg/dL | Creatinine: 0.6 mg/dL | Chronic Hepatitis C 20-Apr-18 | HBsAg- | HBsAb+ | HBcAb+ | (CMIA) 15-Jun-17 | None | |||||||||
| BBS0005-EN900023464050218DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 33 Y | Female | Non-Hispanic | <-70C | 02-May-18 | Roche cobas | 541,300 IU/mL | HCV Viral Load | Genotype | 1a | 15-Mar-18 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | Bilirubin: 0.3 mg/dL | Creatinine: 0.77 mg/dL | Chronic Hepatitis C 15-Mar-18 | HBsAg- | HBsAb+ | HBcAb+ | (CMIA) 15-Mar-18 | None | |||||||||
| BBS0005-EN900023465050818DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 65 Y | Male | Non-Hispanic | <-70C | 08-May-18 | Roche cobas | 1,190,000 IU/mL | HCV Viral Load | Genotype | 1b | 26-Mar-18 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | Bilirubin: 1.04 mg/dL | Creatinine: 0.8 mg/dL | Chronic Hepatitis C 14-Mar-18 | HBsAg- | HBsAb- | HBcAb+ | (CMIA) 14-Mar-18 | None | |||||||||
| BBS0005-EN900023468061218DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 71 Y | Female | Non-Hispanic | <-70C | 12-Jun-18 | Roche cobas | 7,980,000 IU/mL | HCV Viral Load | Genotype | 1b | 10-Jan-18 | 3-series HepB Vaccine | No | $200.00 | Unknown | Fatigue | No | U/A | Bilirubin: 1.8 mg/dL | Creatinine: 0.7 mg/dL | Chronic Hepatitis C 30-May-18 | HBsAg- | HBsAb+ | HBcAb- | (CMIA) 10-Jan-18 | None | |||||||||
| BBS0005-EN900026485072618DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 76 Y | Female | Non-Hispanic | <-70C | 26-Jul-18 | Roche cobas | 6,000,000 IU/mL | HCV Viral Load | Genotype | 1b | 31-May-18 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | ALT: 230 U/L | AST: 200 U/L | Bilirubin: 2.76 mg/dL | Creatinine: 0.9 mg/dL | Chronic Hepatitis C 22-Jun-18 | HBsAg- | HBsAb- | CMIA) 31-May-18 | None | |||||||||
| BBS0005-EN900027417062717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 15.00 | $200.00 | 48 Y | Female | Non-Hispanic | <-70C | 27-Jun-17 | Roche cobas | 3,300,000 IU/mL | 21-Mar-17 | Siemens TruGene HCV 5NC | 1b | 21-Mar-17 | HCV Date of Diagnosis | 1-Feb-94 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 38 U/L | AST: 38 U/L | | Bilirubin: 0.69 mg/dL | Serum Creatinine: 0.86 mg/dL | Chronic Hepatitis C 27-Jun-17 | HBsAg-, HBsAb-, HBcAb-, 27-Jun-17 | None | ||||||||
| BBS0005-EN900027418112117DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 68 Y | Female | Non-Hispanic | <-70C | 21-Nov-17 | Roche cobas | 4,020,000 IU/mL | 10-May-17 | Siemens TruGene HCV 5NC | 1b | 11-Mar-15 | HCV Date of Diagnosis | 11-Mar-15 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 44 U/L | AST: 48 U/L | Serum Creatinine: 0.9 mg/dL | Chronic Hepatitis C 4-Sep-17 | HBsAg-, HBsAb+, HBcAb+, 4-Sep-17 | None | ||||||||
| BBS0005-EN900027419072717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 65 Y | Female | Non-Hispanic | <-70C | 27-Jul-17 | Roche cobas | 719,000 IU/mL | 10-Feb-17 | Siemens TruGene HCV 5NC | 1b | 23-Feb-16 | HCV Date of Diagnosis | 10-Feb-16 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 40 U/L | AST: 40 U/L | | Bilirubin: 0.7 mg/dL | Serum Creatinine: 0.6 mg/dL | Chronic Hepatitis C 20-Jun-17 | HBsAg-, HBsAb+, HBcAb-, 23-Feb-17 | None | ||||||||
| BBS0005-EN900027431092017DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 59 Y | Female | Non-Hispanic | <-70C | 20-Sep-17 | Roche cobas | 37,300 IU/mL | 29-Sep-16 | Siemens TruGene HCV 5NC | 1b | 9-Dec-13 | HCV Date of Diagnosis | 9-Dec-13 | $200.00 | Unknown | Fatigue | No | No | U/A | ALT: 50 U/L | AST: 50 U/L | Serum Creatinine: 0.6 mg/dL | Chronic Hepatitis C 13-Jul-17 | HBsAg-, HBsAb+, HBcAb+, 13-Jul-17 | None | ||||||||
| BBS0005-EN900027432100517DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 71 Y | Female | Non-Hispanic | <-70C | 05-Oct-17 | Roche cobas | 1,570,000 IU/mL | 14-Mar-17 | Siemens TruGene HCV 5NC | 1b | 17-Mar-17 | HCV Date of Diagnosis | 14-Mar-17 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 40 U/L | AST: 46 U/L | ALP: 46 U/L | Bilirubin: 1.1 mg/dL | 16-Jan-2017 Serum Creatinine: 0.9 mg/dL | Chronic Hepatitis C 31-Aug-17 | HBsAg-, HBsAb+, HBcAb+, HBeAb+, 16-Jan-17 | None | ||||||||
| BBS0005-EN900027434111417DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 59 Y | Male | Non-Hispanic | <-70C | 14-Nov-17 | Roche cobas | 12,400,000 IU/mL | 17-Oct-17 | Siemens TruGene HCV 5NC | 1a | 17-Oct-17 | HCV Date of Diagnosis | 17-Oct-17 | $200.00 | Unknown | Fatigue | No | No | U/A | ALT: 16 U/L | AST: 24 U/L | Bilirubin: 0.5 mg/dL | Serum Creatinine: 0.8 mg/dL | Chronic Hepatitis C 17-Oct-17 | HBsAg-, HBsAb-, HBcAb-,, HBeAb-, 17-Jul-17 | None | ||||||||
| BBS0005-EN900032623071317DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 17.00 | $200.00 | 76 Y | Male | Non-Hispanic | <-70C | 13-Jul-17 | Roche cobas | 59,600 IU/mL | 2-Sep-16 | Siemens TruGene HCV 5NC | 1b | 11-Jan-17 | HCV Date of Diagnosis | 1-Mar-15 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 36 U/L | AST: 42 U/L | | Bilirubin: 1.8 mg/dL | Serum Creatinine: 0.76 mg/dL | Liver Cirrhosis from HCV 13-Jul-17 | HBsAg-, HBsAb-, HBcAb+, 5-May-17 | None | ||||||||
| BBS0005-EN900032636101817DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 14.00 | $200.00 | 81 Y | Male | Non-Hispanic | <-70C | 18-Oct-17 | Roche cobas | 1,200,000 IU/mL | 16-Oct-17 | Siemens TruGene HCV 5NC | 1b | 16-Oct-16 | HCV Date of Diagnosis | 2-Feb-15 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 56 U/L | AST: 55 U/L | ALP: 56 U/L | Bilirubin: 0.63 mg/dL | Serum Creatinine: 0.99 mg/dL | Chronic Hepatitis C 4-Sep-17 | HBsAg-, HBsAb-, HBcAb-, 16-Oct-17 | None | ||||||||
| BBS0005-EN900032637072717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 50 Y | Female | Non-Hispanic | <-70C | 27-Jul-17 | Roche cobas | 5,740,000 IU/mL | 4-Feb-17 | Siemens TruGene HCV 5NC | 1b | 10-Jun-15 | HCV Date of Diagnosis | 10-Jun-15 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 40 U/L | AST: 38 U/L | | Bilirubin: 0.7 mg/dL | Serum Creatinine: 0.7 mg/dL | Chronic Hepatitis C 27-Jul-17 | HBsAg-, HBsAb-, HBcAb-, 4-Feb-17 | None | ||||||||
| BBS0005-EN900032638071717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 72 Y | Female | Non-Hispanic | <-70C | 17-Jul-17 | Roche cobas | 266,000 IU/mL | 8-May-17 | Siemens TruGene HCV 5NC | 1b | 8-May-17 | HCV Date of Diagnosis | 9-Mar-97 | $200.00 | Unknown | Fatigue | No | No | U/A | ALT: 38 U/L | AST: 38 U/L | | Bilirubin: 0.48 mg/dL | Serum Creatinine: 0.7 mg/dL | Chronic Hepatitis C 17-Jul-17 | HBsAg-, HBsAb-, HBcAb-, 8-May-17 | None | ||||||||
| BBS0005-EN900032639060917DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 4.00 | $200.00 | 82 Y | Male | Non-Hispanic | <-70C | 09-Jun-17 | Roche cobas | 16,600,000 IU/mL | 22-May-17 | Siemens TruGene HCV 5NC | 1b | 22-Sep-15 | HCV Date of Diagnosis | 22-Sep-15 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 100 U/L | AST: 120 U/L | | Bilirubin: 1.2 mg/dL | Serum Creatinine: 1.8 mg/dL | Liver Cirrhosis from HCV 22-May-17 | HBsAg-, HBsAb-, HBcAb+, 22-May-17 | None | ||||||||
| BBS0005-EN900068381030818DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 61 Y | Female | Non-Hispanic | <-70C | 08-Mar-18 | Roche cobas | 227 IU/mL | HCV Viral Load | Genotype | 1b | 10-Feb-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | Fatigue | No | U/A | ALT: 73 U/L | AST: 103 U/L | Bilirubin: 1.5 mg/dL | Creatinine: 1.1 mg/dL | Chronic Hepatitis C 4-Mar-18 | HBsAg- | HBsAb- | HBcAb- | (CMIA) 6-Dec-17 | None | |||||||||
| BBS0005-EN900068382112717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 53 Y | Female | Non-Hispanic | <-70C | 27-Nov-17 | Roche cobas | 4,850,000 IU/mL | 8-Sep-17 | Siemens TruGene HCV 5NC | 1b | 8-Sep-17 | HCV Date of Diagnosis | 3-Jul-10 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 20 U/L | AST: 30 U/L | Bilirubin: 0.56 mg/dL | Serum Creatinine: 0.71 mg/dL | Chronic Hepatitis C 16-Jun-17 | HBsAg-, HBsAb+, HBcAb-, HBeAg-, 8-Sep-17 | None | ||||||||
| BBS0005-EN900068383112717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 70 Y | Female | Non-Hispanic | <-70C | 27-Nov-17 | Roche cobas | 3,370,000 IU/mL | 14-Sep-17 | Siemens TruGene HCV 5NC | 1b | 14-Sep-17 | HCV Date of Diagnosis | 14-Sep-17 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 35 U/L | AST: 52 U/L | Bilirubin: 0.7 mg/dL | Serum Creatinine: 0.9 mg/dL | Chronic Hepatitis C 14-Sep-17 | HBsAg-, HBcAb-, 14-Sep-17 | None | ||||||||
| BBS0005-EN900068384122017DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 48 Y | Female | Non-Hispanic | <-70C | 20-Dec-17 | Roche cobas | 3,880,000 IU/mL | HCV Viral Load | Genotype | 1b | 19-Oct-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | ALT: 35 U/L | AST: 35 U/L | Bilirubin: 0.46 mg/dL | 19-Oct-2017 | Creatinine: 0.6 mg/dL | Chronic Hepatitis C 23-Sep-17 | HBsAg- | HBsAb- | HBcAb- |HBeAg- (CMIA) 19-Oct-17 | None | |||||||||
| BBS0005-EN900068385030818DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 66 Y | Female | Non-Hispanic | <-70C | 08-Mar-18 | Roche cobas | 90,560 IU/mL | HCV Viral Load | Genotype | 1b | 10-Feb-16 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | Transfusion | ALT: 103 U/L | AST: 55.5 U/L | Bilirubin: 1.5 mg/dL | Creatinine: 1.0 mg/dL | Chronic Hepatitis C 3-Feb-18 | HBsAg- | HBsAb- | HBcAb- | (CMIA) 10-Jan-18 | None | |||||||||
| BBS0005-EN900068386013018DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 8.00 | $200.00 | 64 Y | Female | Non-Hispanic | <-70C | 30-Jan-18 | Roche cobas | 17,500,000 IU/mL | HCV Viral Load | Genotype | 1b | 17-Nov-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | ALT: 18 U/L | AST: 22 U/L | Bilirubin: 0.7 mg/dL | Creatinine: 0.76 mg/dL | Chronic Hepatitis C 8-Nov-17 | HBsAg- | 12-Dec-2017 | HBsAb+ | HBcAb+ 17-Nov-2017 (CMIA) | None | |||||||||
| BBS0005-EN900068387112717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 52 Y | Female | Non-Hispanic | <-70C | 27-Nov-17 | Roche cobas | 464,000 IU/mL | 13-Oct-17 | Siemens TruGene HCV 5NC | 1b | 13-Oct-17 | HCV Date of Diagnosis | 29-Aug-13 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 40 U/L | AST: 24 U/L | Bilirubin: 0.7 mg/dL | Serum Creatinine: 0.7 mg/dL | 29-Aug-2013 | Biopsy HAI = 6 FIB2 Chronic Hepatitis C 13-Oct-17 | HBsAg-, HBsAb-, HBcAb-, 13-Oct-17 | None | ||||||||
| BBS0005-EN900068388011218DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 57 Y | Male | Non-Hispanic | <-70C | 12-Jan-18 | Roche cobas | 3,090,000 IU/mL | HCV Viral Load | Genotype | 1b | 15-Jun-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | ALT: 100 U/L | AST: 60 U/L | Bilirubin: 0.8 mg/dL | Creatinine: 0.6 mg/dL | Chronic Hepatitis C 28-Nov-17 | HBsAg- | HBsAb- | HBcAb- | (CMIA) 28-Nov-17 | None | |||||||||
| BBS0005-EN900068389112717DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 41 Y | Male | Non-Hispanic | <-70C | 27-Nov-17 | Roche cobas | 386,000 IU/mL | 6-Sep-17 | Siemens TruGene HCV 5NC | 1b | 1-Sep-15 | HCV Date of Diagnosis | 16-Nov-09 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 20 U/L | AST: 28 U/L | Bilirubin: 1.5 mg/dL | Serum Creatinine: 1.04 mg/dL | 13-Jul-2010 | Biopsy | HAI = 7 FIB1 ST3 Chronic Hepatitis C 6-Sep-17 | HBsAg-, HBsAb+, HBcAb-, 6-Sep-17 | None | ||||||||
| BBS0005-EN900071943100517DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 69 Y | Female | Non-Hispanic | <-70C | 05-Oct-17 | Roche cobas | 4,360,000 IU/mL | 15-Sep-17 | Siemens TruGene HCV 5NC | 1b | 30-Aug-17 | HCV Date of Diagnosis | 26-Jul-17 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 84 U/L | AST: 60 U/L | 3-Jul-2017 | Bilirubin: 0.62 mg/dL | Serum Creatinine: 0.74 mg/dL | Chronic Hepatitis C 3-Oct-17 | HBsAg-, HBsAb+, HBcAb+, HBeAg-, HBeAb+, 15-Sep-17 | None | ||||||||
| BBS0005-EN900072647011718DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 45 Y | Female | Non-Hispanic | <-70C | 17-Jan-18 | Roche cobas | 61,000 IU/mL | HCV Viral Load | Genotype | 1b | 21-Dec-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | Bilirubin: 0.6 mg/dL | Creatinine: 0.4 mg/dL | Chronic Hepatitis C 21-Dec-17 | HBsAg- | HBsAb- | HBcAb- | (CMIA) 21-Dec-17 | None | |||||||||
| BBS0005-EN900072648011718DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 42 Y | Male | Non-Hispanic | <-70C | 17-Jan-18 | Roche cobas | 7,290,000 IU/mL | HCV Viral Load | Genotype | 1b | 17-Jan-18 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | ALT: 110 U/L | AST: 130 U/L | Bilirubin: 0.6 mg/dL | Creatinine: 0.7 mg/dL | Chronic Hepatitis C 23-Nov-17 | HBsAg- | HBsAb+ | HBcAb- | (CMIA) 23-Nov-17 | None | |||||||||
| BBS0005-EN900072649012318DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 8.00 | $200.00 | 53 Y | Male | Non-Hispanic | <-70C | 23-Jan-18 | Roche cobas | 13,200,000 IU/mL | HCV Viral Load | Genotype | 1b | 27-May-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | ALT: 108 U/L | AST: 56 U/L | Bilirubin: 0.76 mg/dL | Chronic Hepatitis C 23-Jan-18 | HBsAg- | HBsAb+ | HBcAb+ | (CMIA) 27-May-17 | None | |||||||||
| BBS0005-EN900072658031518DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 4.00 | $200.00 | 58 Y | Male | Non-Hispanic | <-70C | 15-Mar-18 | Roche cobas | 470,000 IU/mL | HCV Viral Load | Genotype | 1b | 3-Jan-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | Bilirubin: 0.6 mg/dL | Creatinine: 0.8 mg/dL | Chronic Hepatitis C 27-Mar-18 | HBsAg- | HBsAb- | HBcAb- | (CMIA) 26-Jan-18 | None | |||||||||
| BBS0005-EN900072660122017DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 52 Y | Female | Non-Hispanic | <-70C | 20-Dec-17 | Roche cobas | 639,000 IU/mL | HCV Viral Load | Genotype | 1a | 27-Oct-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | Fatigue | No | U/A | ALP: 73 U/L | Bilirubin: 0.72 mg/dL | Creatinine: 1.02 mg/dL | Chronic Hepatitis C 27-Oct-17 | HBsAg- | HBsAb+ | HBcAb- | (CMIA) 27-Oct-17 | None | |||||||||
| BBS0005-EN900073352032218DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 78 Y | Male | Non-Hispanic | <-70C | 22-Mar-18 | Roche cobas | 4,000,000 IU/mL | HCV Viral Load | Genotype | 1b | 12-Jan-18 | 3-series HepB Vaccine | No | $200.00 | Unknown | Fatigue | No | U/A | Bilirubin: 0.5 mg/dL | Creatinine: 0.9 mg/dL | Chronic Hepatitis C 12-Jan-18 | HBsAg- | HBsAb+ | HBcAb+ | (CMIA) 12-Jan-18 | None | |||||||||
| BBS0005-EN900073353040518DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 12.00 | $200.00 | 48 Y | Female | Non-Hispanic | <-70C | 05-Apr-18 | Roche cobas | 12,500,000 IU/mL | HCV Viral Load | Genotype | 1b | 9-Feb-18 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | Bilirubin: 0.5 mg/dL | Creatinine: 0.6 mg/dL | Chronic Hepatitis C 9-Feb-18 | HBsAg- | HBsAb- | HBcAb+ | (CMIA) 9-Feb-18 | None | |||||||||
| BBS0005-EN900078476102517DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 9.00 | $200.00 | 53 Y | Male | Non-Hispanic | <-70C | 25-Oct-17 | Roche cobas | 1,830,000 IU/mL | 29-Aug-17 | Siemens TruGene HCV 5NC | 1b | 29-Aug-17 | HCV Date of Diagnosis | 29-Aug-17 | $200.00 | Unknown | Fatigue | No | No | U/A | ALT: 32 U/L | AST: 48 U/L | ALP: 51 U/L | Bilirubin: 0.5 mg/dL | Serum Creatinine: 0.6 mg/dL | Chronic Hepatitis C 29-Aug-17 | HBsAg-, HBcAb+, 29-Aug-17 | None | ||||||||
| BBS0005-EN900078477102517DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 76 Y | Female | Non-Hispanic | <-70C | 25-Oct-17 | Roche cobas | 1,230,000 IU/mL | 16-Oct-17 | Siemens TruGene HCV 5NC | 1b | 16-Oct-17 | HCV Date of Diagnosis | 16-Oct-17 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 28 U/L | AST: 52 U/L | Bilirubin: 0.5 mg/dL | Serum Creatinine: 0.8 mg/dL | Chronic Hepatitis C 16-Oct-17 | HBsAg-, HBsAb-, HBcAb-, 7-Nov-17 | None | ||||||||
| BBS0005-EN900078478111417DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 13.00 | $200.00 | 51 Y | Female | Non-Hispanic | <-70C | 14-Nov-17 | Roche cobas | 3,810,000 IU/mL | 14-Jul-17 | Siemens TruGene HCV 5NC | 1b | 14-Jul-17 | HCV Date of Diagnosis | 10-Aug-92 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 152 U/L | AST: 40 U/L | 14-Jul-2017 | Bilirubin: 0.36 mg/dL | Serum Creatinine: 0.65 mg/dL | Chronic Hepatitis C 14-Nov-17 | HBsAg-, HBsAb+, HBcAb-, 15-Nov-17 | None | ||||||||
| BBS0005-EN900078480101317DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 11.00 | $200.00 | 64 Y | Female | Non-Hispanic | <-70C | 13-Oct-17 | Roche cobas | 569,000 IU/mL | 5-Apr-17 | Siemens TruGene HCV 5NC | 1b | 3-May-17 | HCV Date of Diagnosis | 16-Jun-16 | $200.00 | Unknown | Fatigue | No | No | U/A | ALT: 20 U/L | AST: 35 U/L | 5-Apr-2017 | Bilirubin: 0.7 mg/dL | 29-Sep-2017 | Serum Creatinine: 0.69 mg/dL | 24-Mar-2016 | Biopsy HAI=12 Chronic Hepatitis C 13-Oct-17 | HBsAg-, HBcAb+ 3-May-17 | None | ||||||||
| BBS0005-EN900078481101117DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 6.00 | $200.00 | 54 Y | Male | Non-Hispanic | <-70C | 11-Oct-17 | Roche cobas | 445,000 IU/mL | 11-Oct-17 | Siemens TruGene HCV 5NC | 1b | 19-May-10 | HCV Date of Diagnosis | 19-Mar-10 | $200.00 | Unknown | Fatigue | No | No | U/A | ALT: 26 U/L | 28-Mar-2017 | AST: 84 U/L | | Bilirubin: 3.54 mg/dL | Serum Creatinine: 0.7 mg/dL | Liver Cirrhosis from HCV 26-Sep-17 | HBsAg-, HBsAb-, HBcAb-, 28-Mar-17 | None | ||||||||
| BBS0005-EN900087158062513DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 70 Y | Male | Hispanic | <-70C | 25-Jun-13 | Abbott | 8,640 IU/mL | 18-Jun-13 | HCV Genotype | 1 | HCV Date of Diagnosis | 19-Aug-07 | $200.00 | Unknown | 63.78 | 132 | None | U/A | Yes | Jan-2008 IFN & Ribavirin ended Oct-2008 | |||||||||||
| BBS0005-EN900087158072313DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 70 Y | Male | Hispanic | <-70C | 23-Jul-13 | Abbott | <12 IU/mL | 17-Jul-13 | HCV Genotype | 1 | HCV Date of Diagnosis | 19-Aug-07 | $200.00 | Unknown | 63.78 | 132 | None | U/A | Yes | Jan-2008 IFN & Ribavirin ended Oct-2008 | |||||||||||
| BBS0005-EN900087158081913DD | Hepatitis C (HCV) Genotype 1 | Serum | 0.75 | 10.00 | $200.00 | 70 Y | Male | Hispanic | <-70C | 19-Aug-13 | Abbott | <12 IU/mL | 12-Aug-13 | HCV Genotype | 1 | HCV Date of Diagnosis | 19-Aug-07 | $200.00 | Unknown | 63.78 | 132 | None | U/A | Yes | Jan-2008 IFN & Ribavirin ended Oct-2008 | |||||||||||
| BBS0005-EN900089370070213DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 10.00 | $200.00 | 46 Y | Male | Non-Hispanic | <-70C | 02-Jul-13 | Abbott | <12 IU/mL | 2-Jul-13 | HCV Genotype | 1 | HCV Date of Diagnosis | Oct-98 | $200.00 | Unknown | 67.72 | 158 | None | Occupational Contact | Yes | Oct-2001 IFN & Ribavirin ended Dec-2001 | |||||||||||
| BBS0005-EN900089370073013DD | Hepatitis C (HCV) Genotype 1 | Serum | 0.75 | 10.00 | $200.00 | 46 Y | Male | Non-Hispanic | <-70C | 30-Jul-13 | Abbott | <12 IU/mL | 30-Jul-13 | HCV Genotype | 1 | HCV Date of Diagnosis | Oct-98 | $200.00 | Unknown | 67.72 | 158 | None | Occupational Contact | Yes | Oct-2001 IFN & Ribavirin ended Dec-2001 | |||||||||||
| BBS0005-FI900041692040913DD | Hepatitis C (HCV) Genotype 1 | Serum | 1.00 | 3.00 | $200.00 | 66 Y | Male | Non-Hispanic | < -70C | 09-Apr-13 | Test Method Unavailable | 860,881 IU/mL | 1-Sep-12 | Genotype | 1b | Test Method Unavailable | $200.00 | Unknown | Decreased Appetite; Fatigue; Itching | No | No | IV Drug Abuse | ALT: 255; AST: 165; ALP: 73; LDH: 165; Bilirubin: 11.2; Serum Creatinine: 0.9 mg/dL; (Biopsy: G2 S2 Jan-2008) 15-Aug-12 | ||||||||||||
| DSP3800-CC900068775121212DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 10.00 | $200.00 | 37 Y | Male | Hispanic | < -70C | 12-Dec-12 | Roche cobas | 1,009,903 IU/mL | 11-Jun-12 | Genotype | 1 | 2005; Test Method Unvailable | $200.00 | Unknown | Fatigue | Yes | Yes Pegylated Interferon; Ribavirin & Telaprevir | Surgery; Transfusion | ALT: 50; AST: 32; ALP: 60; Bilirubin: 0.5; Serum Creatinine: 0.92 mg/dL; Biopsy: S2 (Jan-2005); Liver Disease Diagnosis: G1 S0 7-Jun-12; Jan-2012 | HCV RNA PCR Pos (11-Jun-2012); HCV RNA PCR Pos (23-Feb-2012); HCV RNA PCR Neg (19-Jan-2012); HCV RNA PCR Neg (12-Jan-2012) | |||||||||||
| DSP3800-CJ900023223062712DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 1.00 | $200.00 | 78 Y | Male | Unknown | <-70°C | 27-Jun-12 | Real-Time PCR | 86,732 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Fatigue | No | No | Dental Care | ALT: 22; AST: 23; ALP: 130; Bilirubin: 0.40; Serum Creatinine: 0.90 mg/dL; Liver Disease Diagnosis: 2007; Hepatocellular Carcinoma 2012 | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900023224071912DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 1.00 | $200.00 | 74 Y | Female | Unknown | <-70°C | 19-Jul-12 | Real-Time PCR | 385,711 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Fatigue; Jaundice; Nausea | No | No | Surgery | ALT: 42; AST: 27; Bilirubin: 0.70; Serum Creatinine: 1.06 mg/dL; Liver Disease Diagnosis: 1989; Hepatic Cirrhosis 2012 | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900023226072012DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 1.00 | $200.00 | 66 Y | Female | Unknown | <-70°C | 20-Jul-12 | Real-Time PCR | 75,041 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Fatigue; Abdominal pain | No | No | Surgery | ALT: 33; AST: 108; ALP: 196; LDH: 437; Bilirubin: 1.72; Serum Creatinine: 0.86 mg/dL; Liver Disease Diagnosis: 2006; Hepatic Cirrhosis 2012 | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900033312072712DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 1.00 | $200.00 | 74 Y | Male | Unknown | <-70°C | 27-Jul-12 | Real-Time PCR | 138,611 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Joint pain | No | No | Transfusion | ALT: 46; AST: 53; ALP: 126; LDH: 271; Bilirubin: 4.50; Serum Creatinine: 1.56 mg/dL; Liver Disease Diagnosis: 2007; Cirrhosis 2012 | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900033313080312DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 1.00 | $200.00 | 80 Y | Male | Unknown | <-70°C | 03-Aug-12 | Real-Time PCR | 302,904 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 28; AST: 44; ALP: 52; LDH: 549; Bilirubin: 0.66; Serum Creatinine: 1.78 mg/dL; Cirrhosis | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900033314080212DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 1.00 | $200.00 | 73 Y | Female | Unknown | <-70°C | 02-Aug-12 | Real-Time PCR | 15,000 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Joint pain | No | No | Household Contact; Dental Care | ALT: 35; AST: 57; ALP: 95; Bilirubin: 0.65; Serum Creatinine: 0.71 mg/dL; Liver Disease Diagnosis: 1994; Chronic Hepatitis | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900033315081012DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 2.00 | $200.00 | 80 Y | Male | Unknown | <-70°C | 10-Aug-12 | Real-Time PCR | 738,478 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | No symptoms | No | No | Dental Care | ALT: 41; AST: 80; ALP: 131; LDH: 307; Bilirubin: 0.40; Serum Creatinine: 1.19 mg/dL; Liver Disease Diagnosis: 1997; Cirrhosis | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900033316090412DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 3.00 | $200.00 | 42 Y | Male | Unknown | <-70°C | 04-Sep-12 | Qiagen RT PCR | 762,550 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain; Nausea | No | No | Transfusion; Surgery | ALT: 284; AST: 154; ALP: 79; Bilirubin: 0.68; Serum Creatinine: 0.82 mg/dL; Liver Disease Diagnosis: 2012; Chronic Hepatitis | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900033317090512DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 3.00 | $200.00 | 75 Y | Male | Unknown | <-70°C | 05-Sep-12 | Real-Time PCR | 274,773 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Jaundice | No | No | Unknown | ALT: 23; AST: 62; ALP: 116; LDH: 347; Bilirubin: 0.80; Serum Creatinine: 1.151 mg/dL; Liver Disease Diagnosis: 2009; Hepatocellular carcinoma | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900033319091012DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 1.00 | $200.00 | 66 Y | Male | Non-Hispanic | <-70°C | 10-Sep-12 | Real-Time PCR | 660,631 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Fatigue; Jaundice | No | No | Dental Care | ALT: 74; AST: 69; Chronic Hepatitis | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900037053091012DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 1.00 | $200.00 | 64 Y | Female | Non-Hispanic | <-70°C | 10-Sep-12 | Real-Time PCR | 66,186 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Jaundice | No | No | Household Contact | ALT: 71; AST: 39; Chronic Hepatitis | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900037054091012DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 6.00 | $200.00 | 78 Y | Male | Non-Hispanic | <-70°C | 10-Sep-12 | Real-Time PCR | 104,000 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Jaundice; Joint pain; Sleep disturbances | No | No | Dental Care | ALT: 72; AST: 80; Bilirubin: 1.9; Serum Creatinine: 1.0 mg/dL; Chronic Hepatitis | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900037055091112DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 1.00 | $200.00 | 80 Y | Male | Non-Hispanic | <-70°C | 11-Sep-12 | Real-Time PCR | 807,280 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Decreased appetite; Fatigue; Jaundice | No | No | Dental Care | ALT: 107; AST: 37; ALP: 82; LDH: 354; Bilirubin: 0.81; Serum Creatinine: 1.27 mg/dL; Hepatic Cirrhosis | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900037057091812DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 2.00 | $200.00 | 65 Y | Female | Non-Hispanic | <-70°C | 18-Sep-12 | Real-Time PCR | 767,000 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Fatigue; Jaundice; Nausea | No | No | Surgery | ALT: 184; AST: 187; ALP: 135; Bilirubin: 0.79; Chronic Hepatitis | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CJ900037058092012DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 2.00 | $200.00 | 74 Y | Male | Non-Hispanic | <-70°C | 20-Sep-12 | Real-Time PCR | 11,900 IU/mL | Siemens TruGene HCV | 1b | $200.00 | Unknown | Joint pain | No | No | Dental Care | ALT: 161; AST: 144; ALP: 166; LDH: 381; Bilirubin: 0.87; Serum Creatinine: 1.14 mg/dL; Hepatocellular Carcinoma | anti HCV+ (Abbott) | |||||||||||||
| DSP3800-CL900041691030713DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 1.00 | $200.00 | 54 Y | Female | Non-Hispanic | <-70°C | 07-Mar-13 | Roche cobas | 111,748 IU/mL | RT-PCR, reverse hybridization | 1b | $200.00 | Unknown | None | Yes | No | Unknown | ALT: 31; AST: 32 ALP: 36; Bilirubin: 0.6; Serum Creatinine: 0.8 mg/dL | ||||||||||||||
| DSP3800-CR900066392012113DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 8.00 | $200.00 | 60 Y | Female | Non-Hispanic | <-70°C | 21-Jan-13 | Roche cobas | 380,000 IU/mL | Research Use Only In-House | 1b | $200.00 | Unknown | Itching; Sleep disturbances; Fatigue | No | No | Unknown | ALT: 37; AST: 48; ALP: 114; Bilirubin: 0.4; Serum Creatinine: 1.16 mg/dL | ||||||||||||||
| DSP3800-CR900066393020113DD | Hepatitis C (HCV) Genotype 1 | Plasma | 0.50 | 2.00 | $100.00 | 51 Y | Female | Non-Hispanic | <-70°C | 01-Feb-13 | Roche cobas | 750,000 IU/mL | Research Use Only In-House | 1b | $100.00 | Unknown | Abdominal pain; Fatigue; Sleep disturbances; Depression | No | No | Unknown | ALT: 27.9; AST: 27.2; ALP: 109; LDH: 238; Bilirubin: 0.4; Serum Creatinine: 0.67 mg/dL | ||||||||||||||
| DSP3800-CR900068776031313DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 2.00 | $200.00 | 39 Y | Male | Non-Hispanic | <-70°C | 13-Mar-13 | Roche cobas | 3,400,000 IU/mL | Research Use Only In-House | 1b | $200.00 | Unknown | No symptoms | No | No | Transfusion | ALT: 90; AST: 49; ALP: 85; Bilirubin: 0.5; Fibroscan 3.7 kPa; Serum Creatinine: 0.9 mg/dL | HBcAg-; anti-HBc+; anti-HBs+; anti-HCV+ | |||||||||||||
| DSP3800-CV900036001050613DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 8.00 | $200.00 | 63 Y | Female | Non-Hispanic | <-70°C | 06-May-13 | Roche cobas | 978,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Sleep disturbances | No | No | Unknown | ALT: 103; AST: 80; Bilirubin: 9.1 umol/L; Serum Creatinine: 89 umol/L | HBsAg- (ECLIA Cobas 6000) | |||||||||||||
| DSP3800-CV900036002081413DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 12.00 | $200.00 | 36 Y | Male | Non-Hispanic | <-70°C | 14-Aug-13 | Roche cobas | 35,700,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite | No | Yes Zidovudine 300 mg; Lamivudine 150 mg; Nevirapine 200 mg | Sexual Transmission; IV Drug Abuse | ALT: 22 U/L; AST: 41 U/L; Serum Creatinine: 84 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2013 | ||||||||||||
| DSP3800-CV900039260070913DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 4.00 | $200.00 | 32 Y | Male | Non-Hispanic | < -70C | 09-Jul-13 | Roche cobas | 2,550,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Fatigue | No | Yes Zidovudine 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Unknown | ALT: 131; AST: 83; Serum Creatinine: 63 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2012 | ||||||||||||
| DSP3800-CV900039261090313DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 10.00 | $200.00 | 36 Y | Male | Non-Hispanic | < -70C | 03-Sep-13 | Roche cobas | 1,810,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | No symptoms | No | Yes Zidovudine 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | IV Drug Abuse | ALT: 38; AST: 26 | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2009 | ||||||||||||
| DSP3800-CV900039262091713DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 13.00 | $200.00 | 28 Y | Male | Non-Hispanic | < -70C | 17-Sep-13 | Roche cobas | 36,200,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Sexual Transmission; IV Drug Abuse | ALT: 78 U/L; AST: 44 U/L; Serum Creatinine: 66 umol/L | HBsAg+; Anti HCV+ (Elisa) | HIV+ 2012 | ||||||||||||
| DSP3800-CV900039263082813DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 17.00 | $200.00 | 31 Y | Female | Non-Hispanic | < -70C | 28-Aug-13 | Roche cobas | 842,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 237 U/L; AST: 168 U/L; Bilirubin: 20 umol/L; Serum Creatinine: 70 umol/L | HBsAg-; HIV- (ECLIA Cobas 6000) | |||||||||||||
| DSP3800-CV900041685072413DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 15.00 | $200.00 | 33 Y | Male | Non-Hispanic | <-70°C | 24-Jul-13 | Roche cobas | 45,000,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue; Sleep disturbances | Yes | Yes Zidovudine 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | IV Drug Abuse | ALT: 49 U/L; AST: 38 U/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2001 | ||||||||||||
| DSP3800-CV900041686072413DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 13.00 | $200.00 | 49 Y | Male | Non-Hispanic | <-70°C | 24-Jul-13 | Roche cobas | 17,300,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Fatigue | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | IV Drug Abuse | ALT: 85 U/L; AST: 64 U/L; Serum Creatinine: 86 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2012 | ||||||||||||
| DSP3800-CV900041687071513DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 10.00 | $200.00 | 37 Y | Male | Non-Hispanic | <-70°C | 15-Jul-13 | Roche cobas | 32,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Fatigue; Joint pain | No | Yes Zidovudine 300 mg; Lamivudine 150 mg; Tenofovir 300 mg; Aluvia 200/50 mg | Sexual Transmission; IV Drug Abuse | ALT: 25 U/L; AST: 25 U/L; Serum Creatinine: 103 umol/L | HIV+ 2006 | |||||||||||||
| DSP3800-CV900046262062013DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 14.00 | $200.00 | 62 Y | Female | Non-Hispanic | < -70C | 20-Jun-13 | Roche cobas | 17,000 IU/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 140; AST: 39 | Anti HCV+ (Cobas 6000) / (Elisa) | |||||||||||||
| DSP3800-CV900046263082213DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 13.00 | $200.00 | 30 Y | Male | Non-Hispanic | < -70C | 22-Aug-13 | Roche cobas | 13,100,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Fatigue | Yes | Yes Zidovudine 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | IV Drug Abuse | ALT: 22 U/L; AST: 25 U/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2011 | ||||||||||||
| DSP3800-CV900046264091313DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 12.00 | $200.00 | 40 Y | Male | Non-Hispanic | < -70C | 13-Sep-13 | Roche cobas | 73,500 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue | Yes | Yes Zidovudine 300 mg; Lamivudine 150 mg; Nevirapine 200 mg | IV Drug Abuse | ALT: 36 U/L; AST: 40 U/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2011 | ||||||||||||
| DSP3800-CV900046267071013DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 5.00 | $200.00 | 32 Y | Male | Non-Hispanic | < -70C | 10-Jul-13 | Roche cobas | 60,700,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Fatigue; Abdominal pain; Joint pain | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Sexual Transmission; IV Drug Abuse | ALT: 51; AST: 42; Serum Creatinine: 74 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2013 | ||||||||||||
| DSP3800-CV900046270073113DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 12.00 | $200.00 | 44 Y | Male | Non-Hispanic | < -70C | 31-Jul-13 | Roche cobas | 17,200,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | No symptoms | No | Yes Zidovudine 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Sexual Transmission | ALT: 175 U/L; AST: 74 U/L; Serum Creatinine: 105 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2008 | ||||||||||||
| DSP3800-CV900046271091213DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 18.00 | $200.00 | 34 Y | Male | Non-Hispanic | < -70C | 12-Sep-13 | Roche cobas | 44,000,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue | No | Yes Zidovudine 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Sexual Transmission; IV Drug Abuse | ALT: 93 U/L; AST: 64 U/L | HIV+ 2013 | |||||||||||||
| DSP3800-CV900053310073113DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 6.00 | $200.00 | 31 Y | Female | Non-Hispanic | < -70C | 31-Jul-13 | Roche cobas | 3,220,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Sexual Transmission | ALT: 26 U/L; AST: 34 U/L; Serum Creatinine: 65 umol/L | HBsAg+; Anti HCV+ (Elisa) | HIV+ 2007 | ||||||||||||
| DSP3800-CV900053311080513DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 19.00 | $200.00 | 27 Y | Male | Non-Hispanic | < -70C | 05-Aug-13 | Roche cobas | 63,500,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Decreased appetite; Fatigue | No | Yes Zidovudine 300 mg; Lamivudine 150 mg;Nevirapine 200 mg | IV Drug Abuse | ALT: 57 U/L; AST: 33 U/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2010 | ||||||||||||
| DSP3800-CV900062433122713DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 7.00 | $200.00 | 36 Y | Male | Non-Hispanic | < -70C | 27-Dec-13 | Roche cobas | 19,100 copies/mL | Lightpower HCV Genotype Rt-PCR | 1 | $200.00 | Unknown | Asymptomatic | No | Yes Tenofovir 300 mg;Lamivudine 150 mg; Efavirenz 600 mg | IV Drug Abuse | ALT: 118 U/L; AST: 71 U/L; Serum Creatinine: 58 umol/L | HBsAg+; Anti HCV+ (Elisa) | HIV+ 2010 | ||||||||||||
| DSP3800-FI900041688011713DD | Hepatitis C (HCV) Genotype 1 | Plasma | 1.00 | 1.00 | $200.00 | 68 Y | Male | Non-Hispanic | <-70°C | 17-Jan-13 | Method Not Available | 2,360,000 IU/mL | Method Not Available | 1a | $200.00 | Unknown | Decreased appetite; Weight loss | Yes | Yes Combivir for HIV | Sexual Transmission; IV Drug Abuse | ALT: 45; AST: 41; ALP: 80; Bilirubin: 0.4; Serum Creatinine: 0.89 mg/dL; LDH: 89 | HIV+ 2004 |
Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.
Please read carefully before purchasing:
Clinical specimens for research use only.
Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.
If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341
These products are supplied without warranty for suitability for specific applications or analytical determinations.
Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.